# Henry Schein Inc: Form 10-K for the period ended Dec 30, 2023

- Company: [Henry Schein Inc](/companies/hsic.md) (CIK 1000228)
- Form: 10-K
- Filed: 2024-02-28
- Accepted by EDGAR: Feb 28, 2024, 14:14 ET
- Period: 2023-12-30
- Accession: 0001000228-24-000011
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1000228/000100022824000011/form10k20231230.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1000228/000100022824000011/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2023-01-01 to 2023-12-30 | $12.34bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2023-01-01 to 2023-12-30 | $8.48bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months, 2023-01-01 to 2023-12-30 | $3.86bn | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months, 2023-01-01 to 2023-12-30 | $2.96bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2023-01-01 to 2023-12-30 | $615.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2023-01-01 to 2023-12-30 | $87.0m | us-gaap:InterestExpense |
| Income tax | 12 months, 2023-01-01 to 2023-12-30 | $120.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2023-01-01 to 2023-12-30 | $416.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-30 | $3.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-30 | $3.18 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2023-01-01 to 2023-12-30 | 131,748,171 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-30 | $500.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-30 | $147.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 12 months, 2023-01-01 to 2023-12-30 | $250.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | at 2023-12-30 | $4.49bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-30 | $10.57bn | us-gaap:Assets |
| Current liabilities | at 2023-12-30 | $2.68bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-12-30 | $5.42bn | us-gaap:Liabilities |
| Short-term borrowings | at 2023-12-30 | $264.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2023-12-30 | $3.65bn | us-gaap:StockholdersEquity |

## Business

As filed, 79,724 characters.

### General

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and

technology. We believe we are the world’s largest provider of health care products and services primarily to office-

based dental and medical practitioners, as well as alternate sites of care. Our philosophy is grounded in our

commitment to help customers operate a more efficient and successful business so the practitioner can provide

better clinical care.

With more than 91 years of experience distributing health care products, we have built a vast set of small, mid-sized

and large customers in the dental and medical markets, serving more than one million customers worldwide across

dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government,

institutional health care clinics and other alternate care clinics.

We are headquartered in Melville, New York and employ more than 25,000 people. Approximately 55% of our

workforce is based in the United States and approximately 45% is based outside of the United States. We have

operations or affiliates in 33 countries and territories. Our broad global footprint has evolved over time through our

organic success as well as through contribution from strategic acquisitions.

We stock a comprehensive selection of more than 300,000 branded products and Henry Schein corporate brand

products through our main distribution centers. Our infrastructure, including over 5.3 million square feet of space

in 36 strategically located distribution and 22 manufacturing facilities around the world, enables us to historically

provide rapid and accurate order fulfillment, better serve our customers and increase our operating efficiency. This

infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to

customer service, enables us to be a single source of supply for our customers’ needs.

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and

value-added services. These segments offer different products and services to the same customer base. Our dental

businesses serve office-based dental practitioners, dental laboratories, schools, government and other

institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency

medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as

group practices and integrated delivery networks, among other providers across a wide range of specialties.

The health care distribution reportable segment, combining our global dental and medical operating segments,

distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services,

branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant,

orthodontic and endodontic products), diagnostic tests, infection-control products, personal protective equipment

products (“PPE”) and vitamins. While our primary go-to-market strategy is in our capacity as a distributor, we also

market and sell under our own corporate brand portfolio of cost-effective, high-quality consumable merchandise

products, and manufacture certain dental specialty products in the areas of oral surgery, implants, orthodontics and

endodontics.

The technology and value-added services reportable segment provides software, technology and other value-added

services to health care practitioners. Henry Schein One, the largest contributor of sales to this category, offers

dental practice management solutions for dental and medical practitioners. In addition, we offer dentists and

physicians a broad suite of electronic health records, patient communication services including electronic marketing

and website design, analytics and patient demand generation. Our value-added practice solutions include practice

consultancy, education, integrated revenue cycle management and the facilitation of financial service offerings (on

a non-recourse basis) to help dentists and physicians operate and expand their business operations, e-services,

practice technology, network and hardware services, as well as consulting, and continuing education services for

practitioners. We believe our hands-on consultative approach to provide solutions to support practice decision-

making is a key differentiator for our business.

### Recent Developments

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Recent

Developments” herein for a discussion related to recent Company developments.

### Industry

The global health care distribution industry, as it relates to office-based health care practitioners, is fragmented and

diverse. The industry ranges from sole practitioners working out of relatively small offices to mid-sized and large

group practices ranging in size from a few practitioners to several hundred practices owned or operated by dental

support organizations (“DSOs”), medical group purchasing organizations (“GPOs”), hospital systems or integrated

delivery networks.

Due in part to the limited capacity of office-based health care practitioners to store and manage large quantities of

supplies in their offices, the distribution of health care supplies and small equipment to office-based health care

practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and

substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are

typically made by the practitioner, hygienist or office manager. Supplies and small equipment are generally

purchased from more than one distributor, with one generally serving as the primary supplier.

The health care distribution industry continues to experience growth due to demand driven by the aging population,

increased health care awareness and the importance of preventative care, an increasing understanding of the

connection between good oral health and overall health, improved access to care globally, the proliferation of

medical technology and testing, new pharmacology treatments and expanded third-party insurance coverage,

partially offset by the effects of unemployment on insurance coverage and technological improvements, including

the advancement of software and services, prosthetic solutions and telemedicine. In addition, the non-acute market

continues to benefit from the shift of procedures and diagnostic testing from acute care settings to alternate-care

sites, particularly physicians’ offices and ambulatory surgery centers.

We believe that consolidation within the industry will continue to result in a number of distributors, particularly

those with limited financial, operating and marketing resources, seeking to combine with larger companies that can

provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire

companies that can enhance their current product and service offerings or provide opportunities to serve a broader

customer base.

In addition, customer consolidation will likely lead to multiple locations under common management and the

movement of more procedures from the hospital setting to the physician or alternate care setting as the health care

industry is increasingly focused on efficiency and cost containment. This trend has benefited distributors capable

of providing a broad array of products and services at low prices. It also has accelerated the growth of health

maintenance organizations (“HMOs”), group practices, other managed care accounts and collective buying groups,

which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable

of providing specialized management information support. We believe that the trend towards cost containment has

the potential to favorably affect demand for technology solutions, including software, which can enhance the

efficiency and facilitation of practice management.

### Competition

The distribution and manufacture of health care supplies and equipment is highly competitive. Many of the health

care products we sell are available to our customers from a number of suppliers. In addition, our competitors could

obtain exclusive rights from manufacturers to market particular products. Manufacturers also could seek to sell

directly to end-users, and thereby eliminate or reduce our role and that of other distributors. In certain parts of the

dental end market, such as those related to dental specialty products, and medical end market manufacturers already

sell directly to end customers.

In North America, we compete with other distributors, as well as several manufacturers, of dental and medical

products, primarily on the basis of price, breadth of product line, e-commerce capabilities, customer service and value-added products and services. In the dental market, our primary competitors in the U.S. are the Patterson

Dental division of Patterson Companies, Inc. and Benco Dental Supply Company. In addition, we compete against

a number of other distributors that operate on a national, regional and local level. Our primary competitors in the

U.S. medical market, which accounts for the large majority of our global medical sales, are McKesson Corporation

and Medline Industries, Inc., which are national distributors. We also compete with a number of regional and local

medical distributors, as well as a number of manufacturers that sell directly to physicians and patients in their

homes. With regard to our dental software, we compete against numerous companies, including the Patterson

Dental division of Patterson Companies, Inc., Carestream Health, Inc., Carestream Dental LLC, Centaur Software

Development Co Pty Ltd. (d.b.a. dental4windows, dental4web), Open Dental Software, Inc., PlanetDDS LLC,

Good Methods Global Inc. (d.b.a. CareStack) and Curve Dental, LLC. In other software end markets, including

revenue cycle management, patient relationship management and patient demand generation, we compete with

companies such as Vyne Therapeutics Inc., EDI-Health Group, Inc. (d.b.a. Dental X Change, Inc.), Weave

Communications, Inc., and Solutionreach, Inc. The medical practice management and electronic medical records

market is fragmented and we compete with numerous companies such as the NextGen division of Quality Systems,

Inc., eClinicalWorks, Allscripts Healthcare Solutions, Inc. and Epic Systems Corporation.

Outside of the U.S., we believe we are the only global distributor of supplies and equipment to dental practices and

our competitors are primarily local and regional companies. We also face significant competition internationally,

where we compete on the basis of price and customer service against several large competitors, including the

GACD Group, Proclinic SA, Lifco AB, Planmeca Oy and Billericay Dental Supply Co. Ltd., as well as a large

number of other dental and medical product distributors and manufacturers in international countries and territories

we serve.

### Competitive Strengths

We have more than 91 years of experience in distributing products to health care practitioners resulting in strong

awareness of the Henry Schein

brand. Our competitive strengths include:

#### A focus on meeting our customers’ unique needs

. We are committed to providing customized solutions to our

customers that are driven by our understanding of the end markets we serve and reflect the technology-driven

products and services best suited for their practice needs. We are committed to continuing to enhance these

offerings through organic investment in our products and our teams, as well as through the acquisition of new

products and services that may help us better serve our customers.

#### Direct sales and marketing expertise.

Our sales and marketing efforts are designed to establish and solidify

customer relationships through personal or virtual visits by field sales representatives, frequent direct marketing and

telesales contact, emphasizing our broad product lines, including exclusive distribution agreements, competitive

prices and ease of order placement, particularly through our e-commerce platforms. The key elements of our direct

sales and marketing efforts are:

#### Field sales consultants.

Our field sales consultants, including equipment sales specialists, covering major

North American, European and other international markets. These consultants complement our direct

marketing and telesales efforts and enable us to better market, service and support the sale of more

sophisticated products and equipment.

#### Marketing.

We market to existing and prospective office-based health care providers through a

combination of owned, earned and paid digital channels, tradeshows, as well as through catalogs, flyers,

direct mail and other promotional materials. Our strategies include an emphasis on educational content

through webinars and content marketing initiatives. We continue to enhance our marketing technology to

improve our targeting capability and the relevance of messaging and offers.

#### Telesales.

We support our direct marketing effort with inbound and outbound telesales representatives,

who facilitate order processing, generate new sales through direct and frequent contact with customers and

stay abreast of market developments and the hundreds of new products, services and technologies

introduced each year to educate practice personnel.

#### Electronic commerce solutions.

We provide our customers and sales teams with innovative and

competitive e-commerce solutions. We continue to invest in our e-commerce platform to offer enhanced

content management so customers can more easily find the products they need and to enable an engaging

purchase experience, supported by excellent customer service.

#### Social media.

Our operating entities and employees engage our customers and supplier partners through

various social media platforms, which are an important element of our communications and marketing

efforts. We continue to expand our social media presence to raise awareness about issues, engage

customers beyond a sale and deliver services and solutions to specialized audiences.

#### Broad product and service offerings at competitive prices.

We offer a broad range of products and services to our

customers, at competitive prices, in the following categories:

#### Consumable supplies and equipment

. We distribute consumable products, small equipment, laboratory

products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, dental

specialty products, diagnostic tests, infection-control products and vitamins. We stock a comprehensive

selection of more than 300,000 branded products and Henry Schein corporate brand products through our

main distribution centers. We also market and sell our own corporate brand portfolio of cost-effective, high-

quality consumable merchandise products and manufacture certain dental specialty products in the areas of

implants, orthodontics and endodontics.

#### Technology and other value-added products and services.

We sell practice management, business

analytics, patient engagement and patient demand creation software solutions to our dental customers. Our

practice management solutions provide practitioners with electronic medical records, patient treatment

history, analytics, billing, accounts receivable analyses and management, appointment calendars, electronic

claims processing and word processing programs, network and hardware services, e-commerce and

electronic marketing services, sourcing third party patient payment plans, transition services and training

and education programs for practitioners. We also sell medical software for practice management, certified

electronic health records (“EHR”) and e-Prescribe medications and prescription solutions. We have

technical representatives supporting customers using our practice management solutions and services. As

of December 30, 2023, we had an active user base of approximately 110,000 practices and 350,000

consumers, including users of AxiUm, Dentally®, Dentrix Ascend®, Dental Vision®, Dentrix® Dental

Systems, Dentrix® Enterprise, Easy Dental®, EndoVision®, Evolution® and EXACT®, Gesden®, Jarvis

Analytics™, Julie® Software, Oasis, OMSVision®, Orisline®, PBS Endo®, PerioVision®, Power

Practice® Px, PowerDent, and Viive® and subscriptions for Demandforce®, Sesame, and Lighthouse360®

for dental practices and DentalPlans.com® for dental patients.

#### Repair services.

We have 119 equipment sales and service centers worldwide that provide a variety of

repair, installation and technical services for our health care customers. Our technicians provide

installation and repair services for dental handpieces, dental and medical small equipment, table-top

sterilizers and large dental equipment.

#### Financial services.

We offer our customers solutions in operating their practices more efficiently by

providing access to a number of financial services and products provided by third party suppliers (including

non-recourse financing for equipment, technology and software products, non-recourse practice financing

for leasehold improvements, business debt consolidation and commercial real estate, non-recourse patient

financing and credit card processing) at rates that we believe are generally lower than what our customers

would be able to secure independently. We also provide staffing services, dental practice valuation and

brokerage services.

#### Commitment to superior customer service

. We maintain a strong commitment to providing superior customer

service. We frequently monitor our customer service through customer surveys, focus groups and statistical

reports. Our customer service policy primarily focuses on:

#### Exceptional order fulfillment

. We ship an average of approximately 141,000 cartons daily.

#### Comprehensive ordering process

. Customers may place orders 24 hours a day, 7 days a week via e-

commerce solutions, telephone, fax, e-mail and mail.

#### Integrated management information systems

. Certain of our information systems generally allow for centralized

management of key functions, including accounts receivable, inventory, accounts payable, payroll, purchasing,

sales, order fulfillment and financial and operational reporting. These systems allow us to manage our growth,

deliver superior customer service, properly target customers, manage financial performance and monitor daily

operational statistics.

#### Cost-effective purchasing

. We believe that cost-effective purchasing is a key element to maintaining and enhancing

our position as a competitively priced provider of health care products. We continuously evaluate our purchase

requirements and suppliers’ offerings and prices in order to obtain products at the lowest possible cost. In 2023,

our top 10 health care distribution suppliers and our single largest supplier accounted for approximately 24% and

4%, respectively, of our aggregate purchases.

#### Efficient distribution

. We distribute our products from our 36 strategically located distribution centers. We strive

to maintain optimal inventory levels in order to satisfy customer demand for prompt delivery and complete order

fulfillment. These inventory levels are managed on a daily basis with the aid of our management information

systems. Once an order is entered, it is electronically transmitted to the distribution center nearest the customer’s

location for order fulfillment.

### Products and Services

The following table sets forth the percentage of consolidated net sales by principal categories of products and

services offered through our health care distribution and technology and value-added services reportable segments:

### December 30,

### December 31,

### December 25,

### 2023

### 2022

### 2021

### Health care distribution:

Dental products

(1)

61.1

59.1

60.8

Medical products

(2)

32.4

35.2

34.0

### Total health care distribution

93.5

94.3

94.8

### Technology and value-added services:

Software and related products and

other value-added products

(3)

6.5

5.7

5.2

### Total

100.0

100.0

100.0

(1)

Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants,

gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, PPE products,

equipment repair and high-tech and digital restoration equipment.

(2)

Includes branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray

products, equipment, PPE products and vitamins.

(3)

Consists of practice management software and other value-added products, which are distributed primarily to health care providers,

and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other

services.

### Business Strategy

Our mission is to provide innovative, integrated health care products and services; and to be trusted advisors and

consultants to our customers - enabling them to deliver the best quality patient care and enhance their practice

management efficiency and profitability. Our BOLD+1 Strategic Plan consists of the following:

### Build (“B”)

Complementary software, specialty, and services businesses for high growth

### Operationalize (“O”)

One Distribution to deliver exceptional customer experience, increased efficiency,

and growth

### Leverage (“L”)

One Schein to broaden and deepen relationships with our customers

### Drive (“D”)

Drive digital transformation for our customers and for Henry Schein

### +1

Create Value for our stakeholders

To accomplish this, we apply our competitive strengths in executing the following strategies:

#### Increase penetration of our existing customer base.

We have over one million customers worldwide and

we intend to increase sales to our existing customer base and enhance our position as their primary

supplier. We believe our offering of a broad range of products, services and support, including software

solutions that can help drive improved workflow efficiency and patient communications for practices,

coupled with our full-service value proposition, helps us to retain and grow our customer base.

#### Increase the number of customers we serve.

This strategy includes increasing the productivity of our field

sales consultants and telesales team, as well as using our customer database to focus our marketing efforts

in all of our operating segments. In the dental business, we provide products and services to independent

practices, mid-market groups, and large DSOs as well as community health centers and government sites of

care. Leveraging our broad array of assets and capabilities, we offer solutions to address these new

markets. In the medical business, we have expanded to serve customers located in settings outside of the

traditional office, such as urgent care clinics, retail, occupational health and home health settings. As

settings of health care shift, we remain committed to serving these practitioners and providing them with

the products and services they need.

#### Leverage our value-added products and services.

We continue to increase cross-selling efforts for key

product lines utilizing a consultative selling process. In the dental business, we have significant cross-

selling opportunities between our dental software users and our dental customers. In the medical business,

we have opportunities to expand our vaccine, injectables and other pharmaceuticals sales to health care

practitioners, as well as cross-selling EHR systems and software when we sell our core products. Our

strategy extends to providing health systems, integrated delivery networks and other large group and multi-

site health care organizations, including physician clinics, these same value added products and services.

As physicians and health systems closely align, we have increased access to opportunities for cross-

marketing and selling our product and service portfolios.

#### Pursue strategic acquisitions and joint ventures.

Our acquisition strategy is focused on investments in

companies that add new customers and sales teams, increase our geographic footprint (whether entering a

new country, such as emerging markets, or building scale where we have already invested in businesses),

and finally, those that enable us to access new products and technologies.

### Markets Served

Demographic trends indicate that our markets are growing, as an aging U.S. population is increasingly using health

care services. According to the U.S. Census Bureau’s International Database, between 2023 and 2033, the 45 and

older population is expected to grow by approximately 11%. Between 2023 and 2043, this age group is expected to

grow by approximately 21%. This compares with expected total U.S. population growth rates of approximately 6%

between 2023 and 2033 and approximately 11% between 2023 and 2043.

In the dental industry, there is predicted to be a rise in oral health care expenditures as the 45-and-older segment of

the population increases. There is increasing demand for new technologies that allow dentists to increase

productivity, and this is being driven in the U.S. by lower insurance reimbursement rates. At the same time, there is

an expected increase in dental insurance coverage.

In the medical market, there continues to be a migration of procedures from acute-care settings to physicians’

offices and home health settings, a trend that we believe provides additional opportunities for us. There also is the

continuing use of vaccines, injectables and other pharmaceuticals in alternate-care settings. We believe we have

established a leading position as a vaccine supplier to the office-based physician practitioner.

We support our dental and medical professionals through the many SKUs that we offer, as well as through

important value-added services, including practice management software, electronic claims processing, financial

services and continuing education, all designed to help maximize a practitioner’s efficiency.

Additionally, we seek to expand our dental full-service model and medical offerings in countries where

opportunities exist. We do this through both direct sales and by partnering with local distribution and

manufacturing companies.

For information on revenues and long-lived assets by geographic area, see

#### Note 4 – Segment and Geographic Data

of “Notes to Consolidated Financial Statements.”

### Seasonality and Other Factors Affecting Our Business and Quarterly Results

We experience fluctuations in quarterly earnings. As a result, we may fail to meet or exceed the expectations of

securities analysts and investors, which could cause our stock price to decline.

Our business is subject to seasonal and other quarterly fluctuations. Sales and profitability generally have been

higher in the third and fourth quarters due to the timing of sales of seasonal products (including influenza vaccine),

purchasing patterns of office-based health care practitioners for certain products (including equipment and

software) and year-end promotions. Sales and profitability may also be impacted by the timing of certain annual

and biennial dental tradeshows where equipment promotions are offered. In addition, some dental practices delay

equipment purchases in the U.S. until year-end due to tax incentives. We expect our historical seasonality of sales

to continue in the foreseeable future.

### Governmental Regulations

We

strive to be compliant in all material respects with the applicable laws, regulations and guidance described

below, and believe we have effective compliance programs and other controls in place to ensure substantial

compliance. However, compliance is not guaranteed either now or in the future, as certain laws, regulations and

guidance may be subject to varying and evolving interpretations that could affect our ability to comply, as well as

future changes, additions and enforcement approaches, including political changes. When we discover situations of

non-compliance we seek to remedy them and bring the affected area back into compliance. President Biden’s

administration (the “Biden Administration”) has indicated that it will be more aggressive in its pursuit of alleged

violations of law, and has revoked certain guidance that would have limited governmental use of informal agency

guidance to pursue potential violations, and has stated that it is more prepared to pursue individuals for corporate

law violations, including an aggressive approach to anti-corruption activities. Federal, state and certain foreign

governments have also increased enforcement activity in the health care sector, particularly in areas of fraud and

abuse, anti-bribery and corruption, controlled substances handling, medical device regulations and data privacy and

security standards.

Changes to applicable laws, regulations and guidance described below, as well as related administrative or judicial

interpretations, may require us to update or revise our operations, services, marketing practices and compliance

programs and controls, and may impose additional and unforeseen costs on us, pose new or previously immaterial

risks to us, or may otherwise have a material adverse effect on our business.

#### Government

Certain of our businesses involve the distribution, manufacturing, importation, exportation, marketing, sale and

promotion of pharmaceuticals and/or medical devices, and in this regard, we are subject to extensive local, state,

federal and foreign governmental laws and regulations, including as applicable to our wholesale distribution of

pharmaceuticals and medical devices, manufacturing activities, and as part of our specialty home medical supply

businesses that distribute and sell medical equipment and supplies directly to patients. Federal, state and certain

foreign governments have also increased enforcement activity in the health care sector, particularly in areas of fraud

and abuse, anti-bribery and anti-corruption, controlled substances handling, medical device regulations and data

privacy and security standards.

Certain of our businesses involve pharmaceuticals and/or medical devices, including in vitro diagnostic devices,

that are paid for by third parties and must operate in compliance with a variety of burdensome and complex coding,

billing and record-keeping requirements in order to substantiate claims for payment under federal, state and

commercial healthcare reimbursement programs.

Government and private insurance programs fund a large portion of the total cost of medical care, and there have

been efforts to limit such private and government insurance programs, including efforts, thus far unsuccessful, to

seek repeal of the entire United States Patient Protection and Affordable Care Act, as amended by the Health Care

and Education Reconciliation Act, each enacted in March 2010 (as amended, the “ACA”).

Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations,

including with respect to the sale, transportation, importation, storage, handling and disposal of hazardous or

potentially hazardous substances; “forever chemicals” such as per-and polyfluoroalkyl substances; and safe

working conditions. In addition, activities to control medical costs, including laws and regulations lowering

reimbursement rates for pharmaceuticals, medical devices, medical supplies and/or medical treatments or services,

are ongoing. The Centers for Medicare & Medicaid Services (“CMS”) recently released the 2024 durable medical

equipment, prosthetics, orthotics and supplies (“DMEPOS”) reimbursement schedule, which, effective January 1,

2024, reduced the DMEPOS reimbursement rates for non-rural suppliers, such as us, by removing the Coronavirus

Aid, Relief, and Economic Security (aka CARES) Act relief rates in effect during the COVID-19 pandemic. This

and other laws and regulations are subject to change and their evolving implementation may impact our operations

and our financial performance.

Our businesses are generally subject to numerous laws and regulations that could impact our financial performance,

and failure to comply with such laws or regulations could have a material adverse effect on our business.

#### Operating, Security and Licensure Standards

Certain of our businesses are subject to local, state and federal governmental laws and regulations relating to the

distribution of pharmaceuticals and medical devices and supplies. Among the United States federal laws applicable

to us are the Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, as amended (“FDC Act”),

Section 361 of the Public Health Service Act and Section 401 of the Consolidated Appropriations Act of the Social

Security Act, as well as laws regulating the billing of and reimbursement from government programs, such as

Medicare and Medicaid, and from commercial payers.

We

are also subject to comparable foreign regulations.

The FDC Act, the Controlled Substances Act, their implementing regulations, and similar foreign laws generally

regulate the introduction, manufacture, advertising, marketing and promotion, sampling, pricing and

reimbursement, labeling, packaging, storage, handling, returning or recalling, reporting, and distribution of, and

record keeping for, pharmaceuticals and medical devices shipped in interstate commerce, and states may similarly

regulate such activities within the state. Furthermore, Section 361 of the Public Health Service Act, which provides

authority to prevent the introduction, transmission or spread of communicable diseases, serves as the legal basis for

the United States Food and Drug Administration’s (“FDA”) regulation of human cells, tissues and cellular and

tissue-based products, also known as “HCT/P products.”

The Federal Drug Quality and Security Act of 2013 brought about significant changes with respect to

pharmaceutical supply chain requirements. Title II of this measure, known as the Drug Supply Chain Security Act

(“DSCSA”), was enacted in November 2013, and had a planned “phase in” schedule over a period of ten years,

resulting in a national electronic, interoperable system to identify and trace certain prescription drugs as they are

distributed in the United States that went into effect on November 27, 2023. Those DSCSA requirements that were

scheduled to change on November 27, 2023, and include requiring trading partners to provide, receive and maintain

documentation about products and ownership only “electronically”(and not via paper) are now subject to a one-year

“stabilization period” announced by FDA through two guidance documents in late August 2023. FDA is permitting

the stabilization period to accommodate an additional year, until November 27, 2024, to allow trading partners to

implement, troubleshoot and mature their electronic (versus paper), interoperable systems, during which time the

FDA does not intend to take action to enforce the requirements for the interoperable, electronic, package level

product tracing. Additionally, the FDA announced that it does not intend to take action to enforce the portion of the

FDC Act with respect to drug product that is introduced in a transaction into commerce by the product’s

manufacturer or repackager before November 27, 2024, and for subsequent transactions of such product through the

product’s expiry. FDA states this stabilization period is intended to avoid disruption to the supply chain, and

ensure continued patient access to drug products as trading partners move towards full implementation of the

DSCSA’s enhanced drug security requirements. The law’s track and trace requirements applicable to

manufacturers, wholesalers, third-party logistics providers (e.g., trading partners), repackagers and dispensers (e.g., pharmacies) of prescription drugs took effect in January 2015, and, as stated, continues to be implemented. The

DSCSA product tracing requirements replace the former FDA drug pedigree requirements and pre-empt certain

state requirements that are inconsistent with, more stringent than, or in addition to, the DSCSA requirements.

The DSCSA also establishes certain requirements for the licensing and operation of prescription drug wholesalers

and third-party logistics providers (“3PLs”), and includes the eventual creation of national wholesaler and 3PL

licenses in cases where states do not license such entities. The DSCSA requires that wholesalers and 3PLs

distribute drugs in accordance with certain standards regarding the recordkeeping, storage and handling of

prescription drugs. The DSCSA requires wholesalers and 3PLs to submit annual reports to the FDA, which include

information regarding each state where the wholesaler or 3PL is licensed, the name and address of each facility, and

contact information. According to FDA guidance, states are pre-empted from imposing any licensing requirements

that are inconsistent with, less stringent than, directly related to, or covered by the standards established by federal

law in this area. Current state licensing requirements concerning wholesalers will remain in effect until the FDA

issues new regulations as directed by the DSCSA. FDA issued a proposed rule establishing wholesaler and 3PL

national standards for licensing and other requirements in February 2022, but that rule has not yet been finalized.

In addition, with respect to our specialty home medical supply business, we are subject to certain state licensure

laws (including state pharmacy laws), and also certain accreditation standards, including to qualify for

reimbursement from Medicare and other third-party payers.

The Food and Drug Administration Amendments Act of 2007 and the Food and Drug Administration Safety and

Innovation Act of 2012 amended the FDC Act to require the FDA to promulgate regulations to implement a unique

device identification (“UDI”) system for medical devices. The UDI rule phased in the implementation of the UDI

regulations, generally beginning with the highest-risk devices (i.e., Class III medical devices) and ending with the

lowest-risk devices. Most compliance dates were reached as of September 24, 2018, with a final set of

requirements for low risk devices being reached on September 24, 2022, which completed the phase in. However,

in May 2021, the FDA issued an enforcement policy stating that it does not intend to object to the use of legacy

identification numbers on device labels and packages for finished devices manufactured and labeled prior to

September 24, 2023. The UDI regulations require “labelers” to include unique device identifiers (“UDIs”), with a

content and format prescribed by the FDA and issued under a system operated by an FDA-accredited issuing

agency, on the labels and packages of medical devices (including, but not limited to, certain software that qualifies

as a medical device under FDA rules), and to directly mark certain devices with UDIs. The UDI regulations also

require labelers to submit certain information concerning UDI-labeled devices to the FDA, much of which

information is publicly available on an FDA database, the Global Unique Device Identification Database. On July

22, 2022, the FDA posted the final guidance regarding the Global Unique Device Identification Database called

Unique Device Identification Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct

Marketing, and Global Unique Device Identification Database Requirements for Certain Devices. The UDI

regulations and subsequent FDA guidance regarding the UDI requirements provide for certain exceptions,

alternatives and time extensions. For example, the UDI regulations include a general exception for Class I devices

exempt from the Quality System Regulation (other than record-keeping requirements and complaint files).

Regulated labelers include entities such as device manufacturers, repackagers, reprocessors and relabelers that

cause a device’s label to be applied or modified, with the intent that the device will be commercially distributed

without any subsequent replacement or modification of the label and include certain of our businesses.

As a distributor of controlled substances, we are required, under the Controlled Substances Act, to obtain and renew

annually registrations for our facilities from the United States Drug Enforcement Administration (“DEA”)

permitting us to handle controlled substances.

We

are also subject to other statutory and regulatory requirements

relating to the storage, sale, marketing, handling, reporting, record-keeping and distribution of such drugs, in

accordance with the Controlled Substances Act and its implementing regulations, and these requirements have been

subject to heightened enforcement activity in recent times.

We

are subject to inspection by the DEA. Certain of

our businesses are also required to register for permits and/or licenses with, and comply with operating and security

standards of, the DEA, the FDA, the United States Department of Health and Human Services (“HHS”), and

various state boards of pharmacy, state health departments and/or comparable state agencies as well as comparable

foreign agencies, and certain accrediting bodies, depending on the type of operations and location of product

distribution, manufacturing or sale. These businesses include those that distribute, manufacture, relabel, and/or

repackage prescription pharmaceuticals and/or medical devices and/or HCT/P products, or own pharmacy

operations, or install, maintain or repair equipment.

In addition, Section 301 of the National Organ Transplant Act, and a number of comparable state laws, impose civil

and/or criminal penalties for the transfer of human organs, as defined in the regulations, for valuable consideration,

while generally permitting payments for the reasonable costs incurred in their procurement, processing, storage and

distribution.

We

are also subject to foreign government regulation of such products. The DEA, the FDA and state

regulatory authorities have broad inspection and enforcement powers, including the ability to suspend or limit the

distribution of products by our distribution centers, seize or order the recall of products and impose significant

criminal, civil and administrative sanctions for violations of these laws and regulations. Foreign regulations subject

us to similar foreign enforcement powers.

#### EU Regulation of Medicinal and Dental Products

European Union (“EU”) member states regulate their own healthcare systems, as does EU law. The latter regulates

certain matters, most notably medicinal products and medical devices. Medicinal products are defined, broadly, as

substances or combinations of substances having certain functionalities and may not include medical devices. EU

“regulations” apply in all member states, whereas “directives” are implemented by the individual laws of member

states.

On medicines for humans, we are regulated under Directive No. 2001/83/EC of 6 November 2001, as amended by

Directive 2003/63/EC of 25 June 2003, and EU Regulation (EC) No. 726/2004 of 31 March 2004. These rules

provide for the authorization of products, and regulate their manufacture, importation, marketing and distribution.

It implements requirements which may be implemented without warning, as well as a national pharmacovigilance

system under which marketing authorizations may be withdrawn, and includes potential sanctions for breaches of

the rules, and on other bases such as harmfulness or lack of efficacy.

EU Regulation No. 1223/2009 of 30 November 2009

#### on cosmetic products

requires that cosmetic products (which

includes dental products) be safe for human health when used under normal or reasonably foreseeable conditions of

use and comply with certain obligations which apply to manufacturer, importer and distributor. It includes market

surveillance, and non-compliance may result in the recall or withdrawal of products, along with other sanctions.

In the EU, the EU Medical Device Regulation No. 2017/745 of 5 April 2017 (“EU MDR”) covers a wide scope of

our activities, from dental material to X-ray machines, and certain software. It was meant to become applicable

three years after publication (i.e., May 26, 2020). However, on April 23, 2020, to allow European Economic Area

(“EEA”) national authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities

related to the COVID-19 pandemic, the European Council and Parliament adopted Regulation 2020/561,

postponing the date of application of the EU MDR by one year (to May 26, 2021).

The EU MDR significantly modifies and intensifies the regulatory compliance requirements for the medical device

industry as a whole. Among other things, the EU MDR:

- strengthens the rules on placing devices on the market and reinforces surveillance once they are available;
- establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the quality,

performance and safety of devices placed on the market;

- improves the traceability of medical devices throughout the supply chain to the end-user or patient through

a unique identification number;

- sets up a central database to provide patients, healthcare professionals and the public with comprehensive

information on products available in the EU;

- strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to

undergo an additional check by experts before they are placed on the market; and

- identifies importers and distributors and medical device products through registration in a database

(EUDAMED, which is not fully functional for the time being and might not be so before the end of 2027 at

the earliest; therefore, the use of this database is only possible through a voluntary basis and, by a way of

consequence, is currently not mandatory).

In particular, the EU MDR imposes strict requirements for the confirmation that a product meets the regulatory

requirements, including regarding a product’s clinical evaluation and a company’s quality systems, and for the

distribution, marketing and sale of medical devices, including post-market surveillance.

Regulation 2023/607 of the European Parliament and of the Council of

#### amending Regulations (EU) 2017/745 and

#### (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical

#### devices

has, notably, extended the EU MDR transitional periods applicable to certain medical devices that have

been assessed and/or certified under the Directive No. 93/42/EEC of 1993

#### concerning medical devices

(“EU

Medical Device Directive”). Subject to certain conditions, medical devices that (i) obtained a certificate under the

EU Medical Device Directive from May 25, 2017, (ii) which was still valid on May 26, 2021, and (iii) has not been

subsequently withdrawn may, for the moment, continue to be placed on the market or put into service until

December 31, 2027 for higher risk devices or December 31, 2028 for medium and lower risk devices. Nevertheless,

EU MDR requirements regarding the distribution, marketing and sale including quality systems and post-market

surveillance have to be observed by manufacturers, importers and distributors as of the application date (i.e., since

May 26, 2021).

Other EU regulations that may apply under appropriate circumstances include EU Regulation No. 1907/2006 of 18

December 2006

#### concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals

, which

requires importers to register substances or mixtures that they import in the EU beyond certain quantities, and the

EU Regulation No. 1272/2008 of 16 December 2008

#### on classification, labelling and packaging of substances and

#### mixtures

(currently under revision), which sets various obligations with respect to the labelling and packaging of

concerned substances and mixtures.

Furthermore, compliance with legal requirements has required and may in the future require us to delay product

release, sale or distribution, or institute voluntary recalls of, or other corrective action with respect to products we

sell, each of which could result in regulatory and enforcement actions, financial losses and potential reputational

harm. Our customers are also subject to significant federal, state, local and foreign governmental regulation, which

may affect our interactions with customers, including the design and functionality of our products.

Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations,

including with respect to the sale, transportation, storage, handling and disposal of hazardous or potentially

hazardous substances, and safe working conditions. In addition, certain of our businesses must operate in

compliance with a variety of burdensome and complex billing and record-keeping requirements in order to

substantiate claims for payment under federal, state and commercial healthcare reimbursement programs.

Certain of our businesses also maintain contracts with governmental agencies and are subject to certain regulatory

requirements specific to government contractors.

#### Antitrust and Consumer Protection

The federal government of the United States, most U.S. states and many foreign countries have antitrust laws that

prohibit certain types of conduct deemed to be anti-competitive, as well as consumer protection laws that seek to

protect consumers from improper business practices. At the U.S. federal level, the Federal Trade Commission

oversees enforcement of these types of laws, and states have similar government agencies. Violations of antitrust

or consumer protection laws may result in various sanctions, including criminal and civil penalties. Private

plaintiffs may also bring civil lawsuits against us in the United States for alleged antitrust law violations, including

claims for treble damages. EU law also regulates competition and provides for detailed rules protecting consumers.

The Biden Administration has indicated increased antitrust enforcement and has been more aggressive in

enforcement activities, including investigation and challenging non-compete restrictions and other restrictive

contractual terms that it believes harm workers and competition.

#### Health Care Fraud

Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse, referral

and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as “false

claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for reimbursement to

federal, state and other health care payers and programs. Other laws, referred to as “anti-kickback laws,” prohibit

soliciting, offering, receiving or paying remuneration in order to induce the referral of a patient or ordering,

purchasing, leasing or arranging for, or recommending, ordering, purchasing or leasing of, items or services that are

paid for by federal, state and other health care payers and programs. Certain additional state and federal laws, such as the federal Physician Self-Referral Law, commonly known as the “Stark Law,” prohibit physicians and other health care professionals from referring a patient to an entity with which the physician (or family member) has a financial relationship, for the furnishing of certain designated health services (for example, durable medical equipment and medical supplies), unless an exception applies. Violations of Anti-Kickback Statutes or the Stark

Law may be enforced as violations of the federal False Claims Act.

The fraud and abuse laws and regulations have been subject to heightened enforcement activity over the past few

years, and significant enforcement activity has been the result of “relators” who serve as whistleblowers by filing

complaints in the name of the United States (and if applicable, particular states) under applicable false claims laws,

and who may receive up to 30% of total government recoveries. Penalties under fraud and abuse laws may be

severe, including treble damages and substantial civil penalties under the federal False Claims Act, as well as

potential loss of licenses and the ability to participate in federal and state health care programs, criminal penalties,

or imposition of a corporate integrity agreement or corporate compliance monitor which could have a material

adverse effect on our business. Also, these measures may be interpreted or applied by a prosecutorial, regulatory or

judicial authority in a manner that could require us to make changes in our operations or incur substantial defense

and settlement expenses. Even unsuccessful challenges by regulatory authorities or private relators could result in

reputational harm and the incurring of substantial costs. Most states have adopted similar state false claims laws,

and these state laws have their own penalties, which may be in addition to federal False Claims Act penalties, as

well as other fraud and abuse laws.

With respect to measures of this type, the United States government (among others) has expressed concerns about

financial relationships between suppliers on the one hand and physicians, dentists and other healthcare

professionals on the other. As a result, we regularly review and revise our marketing practices as necessary to

facilitate compliance.

We

also are subject to certain United States and foreign laws and regulations concerning the conduct of our foreign

operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws

and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records, which have been

the focus of increasing enforcement activity globally in recent years.

While we believe that we are substantially compliant with applicable fraud and abuse laws and regulations, and

have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict

whether changes in applicable law, or interpretation of laws, or changes in our services or marketing practices in

response to changes in applicable law or interpretation of laws, or failure to comply with applicable law, could have

a material adverse effect on our business.

#### Affordable Care Act and Other Insurance Reform

The ACA increased federal oversight of private health insurance plans and included a number of provisions

designed to reduce Medicare expenditures and the cost of health care generally, to reduce fraud and abuse, and to

provide access to increased health coverage. The ACA also materially expanded the number of individuals in the

United States with health insurance.

The ACA has faced frequent legal challenges, including litigation seeking to invalidate and Congressional action

seeking to repeal some of or all of the law or the manner in which it has been implemented. In 2012, the United

States Supreme Court, in upholding the constitutionality of the ACA and its individual mandate provision requiring

that people buy health insurance or else face a penalty, simultaneously limited ACA provisions requiring Medicaid

expansion, making such expansion a state-by-state decision. In addition, one of the major political parties in the

United States remains committed to seeking the ACA’s legislative repeal, but legislative efforts to do so have

previously failed to pass both chambers of Congress. Under President Trump’s administration, a number of

administrative actions were taken to materially weaken the ACA, including, without limitation, by permitting the

use of less robust plans with lower coverage and eliminating “premium support” for insurers providing policies

under the ACA. The Tax Cuts and Jobs Act enacted in 2017, which contains a broad range of tax reform provisions

that impact the individual and corporate tax rates, international tax provisions, income tax add-back provisions and

deductions, also effectively repealed the ACA’s individual mandate by zeroing out the penalty for non-compliance.

An ACA lawsuit decided by the federal Fifth Circuit Court of Appeals found the individual mandate to be unconstitutional, and returned the case to the District Court for the Northern District of Texas for consideration of whether the remainder of the ACA could survive the excision of the individual mandate. The Fifth Circuit’s decision was appealed to the United States Supreme Court. The Supreme Court issued a decision on June 17, 2021.

Without reaching the merits of the case, the Supreme Court held that the plaintiffs in the case did not have standing

to challenge the ACA. Any outcomes of future cases that change the ACA, in addition to future legislation,

regulation, guidance and/or Executive Orders that do the same, could have a significant impact on the U.S.

healthcare industry. For instance, the American Rescue Plan Act of 2021 enhanced premium tax credits, which has

resulted in an expansion of the number of people covered under the ACA. These changes were time-limited, with

some enhancements in place for 2021 only and others available through the end of 2022.

An ACA provision, generally referred to as the Physician Payments Sunshine Act or Open Payments Program (the

“Sunshine Act”), imposes annual reporting and disclosure requirements for drug and device manufacturers and

distributors with regard to payments or other transfers of value made to certain covered recipients (including

physicians, dentists, teaching hospitals, physician assistants, nurse practitioners, clinical nurse specialists, certified

registered nurse anesthetists, and certified nurse midwives), and for such manufacturers and distributors and for

group purchasing organizations, with regard to certain ownership interests held by covered recipients in the

reporting entity. CMS publishes information from these reports on a publicly available website, including amounts

transferred and physician, dentist, teaching hospital, and non-physician practitioner identities. The Sunshine Act

pre-empts similar state reporting laws, although we or our subsidiaries may be required to report under certain state

transparency laws that address circumstances not covered by the Sunshine Act, and some of these state laws, as

well as the federal law, can be unclear.

We

are also subject to foreign regulations requiring transparency of certain

interactions between suppliers and their customers.

In the United States, government actions to seek to increase health-related price transparency may also affect our

business. For example, hospitals are currently required to publish online a list of their standard charges for all items

and services, including discounted cash prices and payer-specific and de-identified negotiated charges, in a publicly

accessible online file. Hospitals are also required to publish a consumer-friendly list of standard charges for certain

“shoppable” services (i.e., services that can be scheduled by a patient in advance) and associated ancillary services

or, alternatively, maintain an online price estimator tool. CMS may impose civil monetary penalties for

noncompliance with these price transparency requirements. Additionally, the No Surprises Act (“NSA”), generally

effective January 1, 2022, imposes additional price transparency requirements. The NSA is intended to reduce the

number of “out-of-network” patients. This will result in fewer out-of-network payments to physicians and other

providers, which may cause financial stress to those providers who are dependent on higher out-of-network fees.

Another notable Medicare health care reform initiative, the Medicare Access and CHIP Reauthorization Act of

2015 (“MACRA”), enacted on April 16, 2015, established a new payment framework, which modified certain

Medicare payments to “eligible clinicians,” including physicians, dentists and other practitioners. Under MACRA,

certain eligible clinicians are required to participate in Medicare through the Merit-Based Incentive Payment

System (“MIPS”) or Advanced Alternative Payment Models, through which Medicare reimbursement to eligible

clinicians includes both positive and negative payment adjustments that take into account quality, promoting

interoperability, cost and improvement activities. Data collected in the first MIPS performance year (2017)

determined payment adjustments that began January 1, 2019. MACRA standards and payment levels continue to

evolve, and reflect a fundamental change in physician reimbursement that is expected to provide substantial

financial incentives for physicians to participate in risk contracts, and to increase physician information technology

and reporting obligations. The implications of the implementation of MACRA are uncertain and will depend on

future regulatory activity and physician activity in the marketplace. New state-level payment and delivery system

reform programs, including those modeled after such federal programs, are also increasingly being rolled out

through Medicaid administrators, as well as through the private sector, which may further alter the marketplace and

impact our business.

Recently, in addition to other government efforts to control health care costs, there has been increased scrutiny on

drug pricing and concurrent efforts to control or reduce drug costs by Congress, the President, executive branch

agencies and various states. At the state level, several states have adopted laws that require drug manufacturers

(including relabelers and repackagers) to provide advance notice of certain price increases and to report information

relating to those price increases, while others have taken legislative or administrative action to establish

prescription drug affordability boards or multi-payer purchasing pools to reduce the cost of prescription drugs. At the federal level, section 1927 of the Social Security Act sets forth Average Sales Price (ASP) reporting requirements for manufacturers (including repackagers and relabelers) and requires that manufacturers provide

CMS with pricing information for their Part B-covered drugs no later than 30 days after the close of the previous

quarter. Also at the federal level, several related bills have been introduced and regulations proposed which, if

enacted or finalized, respectively, would impact drug pricing and related costs.

As a result of political, economic and regulatory influences, the health care distribution industry in the United

States is under intense scrutiny and subject to fundamental changes.

We

cannot predict what further reform

proposals, if any, will be adopted, when they may be adopted, or what impact they may have on us.

#### EU Directive on the pricing and reimbursement of medicinal products

EU law provides for the regulation of the pricing of medicinal products which are implemented by EU member

states (Directive No. 89/105/EC of 21 December 1988

#### relating to the transparency of measures regulating the

#### pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems

Member states may, subject notably to transparency conditions and to the statement of reasons based upon

objective and verifiable criteria, regulate the price charged (or its increases) for authorized medicines and their level

of reimbursement, or they may freeze prices, place controls on the profitability of persons responsible for placing

medicinal products on the market, and include or exclude the medicine on the list of products covered by national

health insurance systems.

EU law does not expressly include provisions like those of the Sunshine Act in the United States, but a growing

number of EU member states (such as France in 2011 and Italy in 2022) have enacted laws to increase the

transparency of relationships in the healthcare sector. The scope of these laws varies from one member state to

another and may, for example, include the relations between healthcare industry players and physicians or their

associations, students preparing for medical professions or their associations, teachers, health establishments or

publishers of prescription and dispensing assistance software.

#### Regulated Software; Electronic Health Records

The FDA has become increasingly active in addressing the regulation of computer software and digital health

products intended for use in health care settings. The 21st Century Cures Act (the “Cures Act”), signed into law on

December 13, 2016, among other things, amended the medical device definition to exclude certain software from

FDA regulation, including clinical decision support software that meets certain criteria. On September 27, 2019,

the FDA issued a guidance document describing the impact the Cures Act on existing software policies.

Concurrently, FDA issued a draft guidance describing FDA’s approach to clinical decision support software. On

September 28, 2022, FDA issued final guidance that made several changes to the draft guidance and that provided a

more restrictive interpretation of exempt clinical decision support software. Certain of our businesses involve the

development and sale of software and related products to support physician and dental practice management, and it

is possible that the FDA or foreign government authorities could determine that one or more of our products is a

medical device, which could subject us or one or more of our businesses to substantial additional requirements with

respect to these products.

In addition, our businesses that involve physician and dental practice management products, and our specialty home

medical supply business, include electronic information technology systems that store and process personal health,

clinical, financial and other sensitive information of individuals. These information technology systems may be

vulnerable to breakdown, wrongful intrusions, data breaches and malicious attack, which could require us to

expend significant resources to eliminate these problems and address related security concerns and could involve

claims against us by private parties and/or governmental agencies. For example, we are directly or indirectly

subject to numerous and evolving federal, state, local and foreign laws and regulations that protect the privacy and

security of personal information, such as the federal Health Insurance Portability and Accountability Act of 1996,

as amended, and implementing regulations (“HIPAA”), the Controlling the Assault of Non-Solicited Pornography

and Marketing Act (“CAN-SPAM”), the Telephone Consumer Protection Act of 1991 (“TCPA”), Section 5 of the

Federal Trade Commission Act (“FTC Act”), the California Privacy Act (“CCPA”), and the California Privacy

Rights Act (“CPRA”) that became effective on January 1, 2023. Several other states have also passed

comprehensive privacy legislation, and several privacy bills have been proposed both at the federal and state level that may result in additional legal requirements that impact our business. Laws and regulations relating to privacy and data protection are continually evolving and subject to potentially differing interpretations. These requirements may not be harmonized, may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with other rules or our practices. Our businesses’ failure to comply with these laws and regulations could expose us to breach of contract claims, substantial fines, penalties and other liabilities and expenses, costs for remediation and harm to our reputation. Also, evolving laws and regulations in this area could restrict the ability of our customers to obtain, use or disseminate patient information, or could require us to incur significant additional costs to re-design our products to reflect these legal requirements, which could have a material adverse effect on our operations.

Also, the European Parliament and the Council of the EU adopted the pan-European General Data Protection

Regulation (“GDPR”), effective from May 25, 2018, which increased privacy rights for individuals (“Data

Subjects”), including individuals who are our customers, suppliers and employees. The GDPR extended the scope

of responsibilities for data controllers and data processors, and generally imposes increased requirements and

potential penalties on companies, such as us, that are either established in the EU and process personal data of Data

Subjects (regardless the Data Subject location), or that are not established in the EU but that offer goods or services

to Data Subjects in the EU or monitor their behavior in the EU. Noncompliance can result in penalties of up to the

greater of EUR 20 million, or 4% of global company revenues (sanction that may be public), and Data Subjects

may seek damages. Member states may individually impose additional requirements and penalties regarding

certain limited matters (for which the GDPR let some room of flexibility), such as employee personal data. With

respect to the personal data it protects, the GDPR requires, among other things, controller accountability, consents

from Data Subjects or another acceptable legal basis to process the personal data, notification within 72 hours of a

personal data breach where required, data integrity and security, and fairness and transparency regarding the

storage, use or other processing of the personal data. The GDPR also provides rights to Data Subjects relating

notably to information, access, rectification, erasure of the personal data and the right to object to the processing.

On August 20, 2021, China promulgated the PRC Personal Information Protection Law (“PIPL”), which took effect

on November 1, 2021. The PIPL imposes specific rules for processing personal information and it also specifies

that the law shall also apply to personal information activities carried out outside China but for the purpose of

providing products or services to PRC citizens. Any non-compliance with these laws and regulations may subject

us to fines, orders to rectify or terminate any actions that are deemed illegal by regulatory authorities, other

penalties, as well as reputational damage or legal proceedings against us, which may affect our business, financial

condition or results of operations. The PIPL carries maximum penalties of CNY50 million or 5% of the annual

revenue of entities that process personal data. In the United States, the CCPA, which increases the privacy

protections afforded California residents, became effective January 1, 2020. The CCPA generally requires

companies, such as us, to institute additional protections regarding the collection, use and disclosure of certain

personal information of California residents. Compliance with the obligations imposed by the CCPA depends in

part on how particular regulators interpret and apply them. Regulations were released in August of 2020, but there

remains some uncertainty about how the CCPA will be interpreted by the courts and enforced by the regulators. If

we fail to comply with the CCPA or if regulators assert that we have failed to comply with the CCPA, we may be

subject to certain fines or other penalties and litigation, any of which may negatively impact our reputation, require

us to expend significant resources, and harm our business. Furthermore, California voters approved the CPRA on

November 3, 2020, which amends and expands the CCPA, including by providing consumers with additional rights

with respect to their personal information, and creating a new state agency, the California Privacy Protection

Agency, to enforce the CCPA and the CPRA. The CPRA came into effect on January 1, 2023, applying to

information collected by businesses on or after January 1, 2022.

As noted above, other states, as well as the federal government, have increasingly considered the adoption of

similarly expansive personal privacy laws, backed by significant civil penalties for non-compliance. While we

believe we have substantially compliant programs and controls in place to comply with the GDPR, CCPA, PIPL,

CPRA and other state law requirements, our compliance with data privacy and cybersecurity laws is likely to

impose additional costs on us, and we cannot predict whether the interpretations of the requirements, or changes in

our practices in response to new requirements or interpretations of the requirements, could have a material adverse

effect on our business.

We

also sell products and services that health care providers, such as physicians and dentists, use to store and

manage patient medical or dental records. These customers, and we, are subject to laws, regulations and industry

standards, such as HIPAA and the Payment Card Industry Data Security Standards, which require the protection of

the privacy and security of those records, and our products may also be used as part of these customers’

comprehensive data security programs, including in connection with their efforts to comply with applicable privacy

and security laws. Perceived or actual security vulnerabilities in our products or services, or the perceived or actual

failure by us or our customers who use our products or services to comply with applicable legal or contractual data

privacy and security requirements, may not only cause us significant reputational harm, but may also lead to claims

against us by our customers and/or governmental agencies and involve substantial fines, penalties and other

liabilities and expenses and costs for remediation.

Various federal initiatives involve the adoption and use by health care providers of certain EHR systems and

processes. The initiatives include, among others, programs that incentivize physicians and dentists, through MIPS,

to use EHR technology in accordance with certain evolving requirements, including regarding quality, promoting

interoperability, cost and improvement activities. Qualification for the MIPS incentive payments requires the use

of EHRs that are certified as having certain capabilities designated in evolving standards adopted by CMS and the

Office of the National Coordinator for Health Information Technology of HHS (“ONC”). Certain of our businesses

involve the manufacture and sale of such certified EHR systems and other products linked to government supported

incentive programs. In order to maintain certification of our EHR products, we must satisfy these changing

governmental standards. If any of our EHR systems do not meet these standards, yet have been relied upon by

health care providers to receive federal incentive payments, we may be exposed to risk, such as under federal health

care fraud and abuse laws, including the False Claims Act. Additionally, effective September 1, 2023, the Office of

the Inspector General (“OIG”) for HHS issued a final rule implementing civil money penalties for information

blocking as established by the Cures Act. OIG incorporated regulations published by ONC as the basis for

enforcing information blocking penalties. Each information blocking violation carries up to a $1 million penalty.

Moreover, in order to satisfy our customers, and comply with evolving legal requirements, our products may need

to incorporate increasingly complex functionality, such as with respect to reporting and information blocking.

Although we believe we are positioned to accomplish this, the effort may involve increased costs, and our failure to

implement product modifications, or otherwise satisfy applicable standards, could have a material adverse effect on

our business.

Other health information standards, such as regulations under HIPAA, establish standards regarding electronic

health data transmissions and transaction code set rules for specific electronic transactions, such as transactions

involving claims submissions to third party payers. Failure to abide by these and other electronic health data

transmission standards could expose us to breach of contract claims, substantial fines, penalties, and other liabilities

and expenses, costs for remediation and harm to our reputation.

Additionally, as electronic medical devices are increasingly connected to each other and to other technology, the

ability of these connected systems to safely and effectively exchange and use exchanged information becomes

increasingly important. As a medical device manufacturer, we must manage risks including those associated with

an electronic interface that is incorporated into a medical device.

There may be additional legislative or regulatory initiatives in the future impacting health care.

#### E-Commerce

Electronic commerce solutions have become an integral part of traditional health care supply and distribution

relationships. Our distribution business is characterized by rapid technological developments and intense

competition. The continuing advancement of online commerce requires us to cost-effectively adapt to changing

technologies, to enhance existing services and to develop and introduce a variety of new services to address the

changing demands of consumers and our customers on a timely basis, particularly in response to competitive

offerings.

Through our proprietary, technologically-based suite of products, we offer customers a variety of competitive

alternatives.

We

believe that our tradition of reliable service, our name recognition and large customer base built

on solid customer relationships, position us well to participate in this significant aspect of the distribution business.

We

continue to explore ways and means to improve and expand our online presence and capabilities, including our

online commerce offerings and our use of various social media outlets.

#### International Transactions

United States and foreign import and export laws and regulations require us to abide by certain standards relating to

the importation and exportation of products.

We

also are subject to certain laws and regulations concerning the

conduct of our foreign operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German

anti-corruption laws and other anti-bribery laws and laws pertaining to the accuracy of our internal books and

records, as well as other types of foreign requirements similar to those imposed in the United States.

While we believe that we are substantially compliant with the foregoing laws and regulations promulgated

thereunder and possess all material permits and licenses required for the conduct of our business, there can be no

assurance that laws and regulations that impact our business or laws and regulations as they apply to our customers’

practices will not have a material adverse effect on our business.

See “

## Risk factors

As filed, 70,352 characters.

Our business operations could be affected by factors that are not presently known to us or that we currently

consider not to be material to our operations, so you should not consider the risks disclosed in this section to

necessarily represent a complete statement of all risks and uncertainties. The Company believes that the following

risks could have a material adverse impact on our business, reputation, financial results, financial condition and/or

the trading price of our common stock. The order in which these factors appear does not necessarily reflect their

relative importance or priority.

### COMPANY RISKS

***We are dependent upon third parties for the manufacture and supply of a significant volume of our products.***

We obtain a significant volume of the products we distribute from third parties, with whom we generally do not

have long-term contracts. While there is typically more than one source of supply, some key suppliers, in the

aggregate, supply a significant portion of the products we sell. In 2023, our top 10 health care distribution suppliers

and our single largest supplier accounted for approximately 25% and 4%, respectively, of our aggregate purchases.

Because of our dependence upon such suppliers, our operations are subject to the suppliers’ ability and willingness

to supply products in the quantities that we require, and the risks include delays caused by interruption in

production based on conditions outside of our control, including a supplier’s failure to comply with applicable

government requirements (which may result in product recalls and/or cessation of sales) or an interruption in the

suppliers’ manufacturing capabilities. In the event of any such interruption in supply, we would need to identify

and obtain acceptable replacement sources on a timely basis. There is no guarantee that we would be able to obtain

such alternative sources of supply on a timely basis, if at all, and an extended interruption in supply, particularly of

a high-sales volume product, could result in a significant disruption in our sales and operations, as well as damage

to our relationships with customers and our reputation. In addition, certain of our suppliers have had their ability to

service certain markets restricted or negatively impacted because of allegations of forced labor in their supply

chain. Forced labor legislation affecting the supply chain has increased around the world, and the United States

recently passed the Uyghur Forced Labor Prevention Act. Our supply chain could be materially disrupted if our

suppliers fail to comply with, or are unable to satisfy our demand for products, as a result of applicable forced labor

legislation and regulations.

### Our future growth (especially for our technology and value-added services segment) is dependent upon our

### ability to develop or acquire and maintain and protect new products and technologies that achieve market

### acceptance with acceptable margins.

Our future success depends on our ability to timely develop (or obtain the right to sell) competitive and innovative

(particularly for our technology and value-added services segment) products and services and to market them

quickly and cost-effectively. Our ability to anticipate customer needs and emerging trends and develop or acquire

new products, services and technologies at competitive prices requires significant resources, including employees

with the requisite skills, experience and expertise, particularly in our technology segment, including dental practice

management, patient engagement and demand creation software solutions. The failure to successfully address these

challenges could materially disrupt our sales and operations. Additionally, our software and e-services products,

like software products generally, may contain undetected errors or bugs when introduced or as new versions are

released. Any such defective software may result in increased expenses related to the software and could adversely

affect our relationships with customers as well as our reputation. With respect to certain software and e-services

that we develop, we rely primarily upon copyright, trademark and trade secret laws, as well as contractual and

common law protections and confidentiality obligations. We cannot provide assurance that such legal protections

will be available, adequate or enforceable in a timely manner to protect our software or e-services products.

***Risks inherent in acquisitions, dispositions and joint ventures could offset the anticipated benefits.***

One of our business strategies has been to expand our domestic and international markets in part through

acquisitions and joint ventures and we expect to continue to make acquisitions and enter into joint ventures in the

future. Such transactions require significant management attention, may place significant demands on our

operations, information systems, legal, regulatory, compliance, financial, and human resources functions, and there is risk that one or more may not succeed. We cannot be sure, for example, that we will achieve the benefits of revenue growth that we expect from these acquisitions or joint ventures or that we will avoid unforeseen additional costs, taxes, or expenses. Our ability to successfully implement our acquisition and joint venture strategy depends upon, among other things, the following:

the availability of suitable acquisition or joint venture candidates at acceptable prices;

our ability to consummate such transactions, which could potentially be prohibited due to U.S. or

foreign antitrust regulations;

the liquidity of our investments and the availability of financing on acceptable terms;

our ability to retain customers or product lines of the acquired businesses or joint ventures;

our ability to retain, recruit and incentivize the management of the companies we acquire; and

our ability to successfully integrate these companies’ operations, services, products and personnel with

our culture, management policies, legal, regulatory, and compliance policies, cybersecurity systems and

policies, internal procedures, working capital management, financial, and operational controls and

strategies.

Furthermore, some of our acquisitions and future acquisitions may give rise to an obligation to make contingent

payments or to satisfy certain repurchase obligations, which payments could have material adverse impacts on our

financial results individually or in the aggregate.

Additionally, when we decide to sell assets or a business, we may encounter difficulty in finding buyers or

executing alternative exit strategies on acceptable terms in a timely manner, which could delay the accomplishment

of our strategic objectives. Alternatively, we may dispose of assets or a business at a price or on terms that are less

than we had anticipated. Dispositions may also involve continued financial involvement in a divested business,

such as through transition service agreements, indemnities or other current or contingent financial obligations.

Under these arrangements, performance by the acquired or divested business, or other conditions outside our

control, could affect our future financial results.

### Certain provisions in our governing documents and other documents to which we are a party may discourage

### third parties from seeking to acquire us that might otherwise result in our stockholders receiving a premium

### over the market price of their shares.

The provisions of our certificate of incorporation and by-laws may make it more difficult for a third-party to

acquire us, may discourage acquisition bids and may impact the price that certain investors might be willing to pay

in the future for shares of our common stock. These provisions, among other things require (i) the affirmative vote

of the holders of at least 60% of the shares of common stock entitled to vote to approve a merger, consolidation, or

a sale, lease, transfer or exchange of all or substantially all of our assets; and (ii) the affirmative vote of the holders

of at least 66 2/3% of our common stock entitled to vote to (a) remove a director; and (b) to amend or repeal our

by-laws, with certain limited exceptions. In addition, certain of our employee incentive plans provide for

accelerated vesting of stock options and other awards upon termination without cause within two years following a

change in control, or grant the plan committee discretion to accelerate awards upon a change of control. Further,

certain agreements between us and our executive officers provide for increased severance payments and certain

benefits if those executive officers are terminated without cause by us or if they terminate for good reason, in each

case within two years following a change in control or within ninety days prior to the effective date of the change in

control or after the first public announcement of the pendency of the change in control.

***Adverse changes in supplier rebates or other purchasing incentives could negatively affect our business.***

The terms on which we purchase or sell products from many suppliers may entitle us to receive a rebate or other

purchasing incentive based on the attainment of certain growth goals. Suppliers may reduce or eliminate rebates or

incentives offered under their programs, or increase the growth goals or other conditions we must meet to earn

rebates or incentives to levels that we cannot achieve. Increased competition either from generic or equivalent

branded products could result in us failing to earn rebates or incentives that are conditioned upon achievement of

growth goals. Additionally, factors outside of our control, such as customer preferences, consolidation of suppliers

or supply issues, can have a material impact on our ability to achieve the growth goals established by our suppliers, which may reduce the amount of rebates or incentives we receive. The occurrence of any of these events could have an adverse impact on our business, financial condition or operating results.

### Sales of corporate brand products entail additional risks, including the risk that such sales could adversely affect

### our relationships with suppliers.

We offer certain corporate brand products that are available exclusively from us. The sale of such products subjects

us to the risks generally encountered by entities that source, market and sell corporate brand products, including but

not limited to potential product liability risks, mandatory or voluntary product recalls, potential supply chain and

distribution chain disruptions, and potential intellectual property infringement risks. Any failure to adequately

address some or all of these risks could have an adverse effect on our business, financial condition or operating

results. In addition, an increase in the sales of our corporate brand products may negatively affect our sales of

products owned by our suppliers which, consequently, could adversely impact certain of our supplier relationships.

Our ability to locate qualified, economically stable suppliers who satisfy our requirements, and to acquire sufficient

products in a timely and effective manner, is critical to ensuring, among other things, that customer confidence is

not diminished. In addition, we are exposed to the risk that our competitors or our large customers may introduce

their own private label, generic, or low-cost products that compete with our products at lower price points. Such

products could capture significant market share or decrease market prices overall, eroding our sales and margins.

Any failure to develop sourcing relationships with a broad and deep supplier base could have an adverse effect on

our business, financial condition or operating results.

### INDUSTRY RISKS

### Security risks generally associated with our information systems and our technology products and services have

### in the recent past adversely affected our business and results of operations, and could in the future materially

### adversely affect our business and our results of operations if such products, services, or systems (or third-party

### systems we rely on) are interrupted, damaged by unforeseen events, are subject to cyberattacks or fail for any

### extended period of time.

We rely on information systems (“IS”) in our business to obtain, rapidly process, analyze, manage and store

customer, product, supplier and employee data to, among other things:

maintain and manage worldwide systems to facilitate the purchase and distribution of thousands of

inventory items from numerous distribution centers;

receive, process and ship orders on a timely basis;

manage the accurate billing and collections for our customers;

process payments to suppliers;

provide products and services that maintain certain of our customers’ electronic medical or dental

records (including protected health information of their patients); and

maintain and manage global human resources, compensation and payroll systems.

In addition to health information in our customers’ electronic medical and dental records, certain of our IS stores

other sensitive personal and financial information, such as healthcare and other information related to our

employees, as well as other sensitive information such as credit card information from our third-party business

partners, that is confidential, and in many cases subject to privacy laws.

Our IS are vulnerable to, among other things, natural disasters, power losses, computer viruses, telecommunication

failures, cybersecurity threats and other criminal activity. Information security risks have significantly increased in

recent years in part because of an overall increase in cyber incidents, their increased sophistication, and the

involvement of organized crime, hackers, terrorists and foreign state agents. The healthcare industry in particular

has been targeted by threat actors seeking to undermine companies’ cybersecurity defensive measures.

We have processes in place intended to ensure that our security measures keep pace with new and emerging risks.

We regularly review, monitor and implement multiple layers of security through technology, processes and our

people. We utilize security technologies designed to protect and maintain the integrity of our IS and data, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers have been, and may in the future be, vulnerable to privacy and security incidents, cybersecurity attacks and data breaches, acts of vandalism or theft, computer viruses and other malicious code, misplaced or lost data, programming and/or human errors, attacks or other acts undermining IS of third party business partners including our customers, or other similar events that could impact the security, reliability and availability of our systems. In addition, hardware, software or applications developed internally or procured from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security. As a practical matter, so long as we depend on IS to operate our business, and our business partners do the same, there can be no guaranty that such measures will successfully stop any one particular cybersecurity incident given the constantly evolving nature of the threat. We may also incur substantial costs as we update our cybersecurity defense systems and our general computer controls to meet evolving challenges, and legislative or regulatory action related to cybersecurity may increase our costs to develop or implement new technology products and services.

A cyberattack that bypasses or compromises our IS cybersecurity / or general information technology (“IT”)

controls (including third-party systems we rely on) causing an IS security breach may lead, and has in the past led,

to a disruption of our IS business systems (including third-party systems we rely on), interruption of operations

(including, without limitation, receiving, verifying, and processing customer orders, customer service, accounts

payable, warehouse management and shipping, and systems tied to internal controls over financial reporting), the

loss or alteration of business, financial, and other protected information, a negative impact on our financial

performance, and to an adverse impact on our financial accounting and reporting controls.

A cyberattack that bypasses or compromises our IS cybersecurity / or general computer controls or those of third

parties with whom we engage may also lead to claims against us by affected parties and/or governmental agencies,

and involve fines and penalties, as well as substantial defense and settlement expenses. Any of these impacts may

alone, or collectively, have a material impact on our business. A successful cyberattack has, and may again in the

future, disrupt our business operations, adversely impact our financial accounting and reporting of results of

operations, divert the attention of management, and adversely impact our results of operations.

In addition, we develop products and provide services to our customers that are technology-based, and a

cyberattack that bypasses the IS supporting our products or services causing a security breach and/or perceived

security vulnerabilities in our products or services could also cause significant loss of business and reputational

harm, and actual or perceived vulnerabilities may lead to claims against us by our customers and/or governmental

agencies. In addition, certain of our practice management products and services purchased by health care

providers, such as physicians and dentists, are used to store and manage patient medical or dental records. These

customers are subject to laws and regulations which require that they protect the privacy and security of those

records, and our products may be used as part of these customers’ comprehensive data security programs, including

in connection with their efforts to comply with applicable privacy and security laws.

In addition to immaterial and unrelated prior incidents at certain of our subsidiaries, in October 2023, Henry Schein

experienced a cybersecurity incident that primarily affected the operations of our North American and European

dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle

management and patient relationship management solutions business was not affected, and our manufacturing

businesses were mostly unaffected. Once we became aware of the issue, we took steps to assess, contain and

remediate this incident. We restored affected systems and applications, our distribution operations resumed and we

reactivated our ecommerce platform. We also notified law enforcement and our employees, customers, suppliers

and investors, informing them of both the incident and management’s efforts to mitigate its impact on our daily

operations and data maintained on the Company’s systems. Subsequently, on or about November 8, 2023, we

determined that the threat actor obtained personal and sensitive information maintained on our systems belonging to

certain third parties and since that date we have notified affected parties and potentially affected parties as

appropriate. The scope of personal and sensitive data impacted is still under investigation. On November 22, 2023,

we experienced a related disruption to our ecommerce platform and related applications, which has since been

remediated. The October 2023 cybersecurity incident disrupted key business operations, adversely impacted our

financial results for the fourth quarter and full year 2023, diverted attention of management, and caused the

Company to incur significant remediation costs. We continue to review the effects of the incident on the

Company’s business as we do expect some short-term residual impact on our financial results in 2024. In January

2024, two putative class actions were filed against us based on the incident and one of these actions is still pending.

We are spending, and plan to expend in the future, additional resources to continue to protect against, or to address

problems caused by, business interruptions, and data security breaches.

In addition, customers and suppliers may impose additional cybersecurity requirements on us as a result of the

incident we experienced in October 2023, and some customers and suppliers have made such requests to date. We

cannot guarantee that we will be able to satisfy such additional requirements, and failure to satisfy such

requirements could result in a loss of revenue or diminished product availability that could materially affect our

business adversely. We also may be perceived as a more vulnerable target of the cyber hackers as a result of the

October 2023 incident. If the Company is subject to more attacks in the future as a result of the recent incident, this

could materially affect our business adversely.

We maintain cyber insurance, subject to certain retentions and policy limitations. With respect to the October 2023

cybersecurity incident, we have a $60 million insurance policy, following a $5 million retention.

### The health care products distribution industry is highly competitive (including, without limitation, competition

***from third-party online commerce sites) and consolidating, and we may not be able to compete successfully.***

We compete with numerous companies, including several major manufacturers and distributors. Some of our

competitors have greater financial and other resources than we do, which could allow them to compete more

successfully. Most of our products are available from several sources and our customers tend to have relationships

with several distributors. Competitors could obtain exclusive rights to market particular products, which we would

then be unable to market. Manufacturers also could increase their efforts to sell directly to end-users and thereby

eliminate or reduce our role in distribution. Industry consolidation among health care product distributors and

manufacturers, price competition, product unavailability, whether due to our inability to gain access to products or

to interruptions in manufacturing supply, or the emergence of new competitors, also could increase competition.

Consolidation has also increased among manufacturers of health care products, which could have a material

adverse effect on our margins and product availability. We could be subject to charges and financial losses in the

event we fail to satisfy minimum purchase commitments contained in some of our contracts. Additionally,

traditional health care supply and distribution relationships are being challenged by electronic online commerce

solutions. The continued advancement of online commerce by third parties will require us to cost-effectively adapt

to changing technologies, to enhance existing services and to differentiate our business (including with additional

value-added services) to address changing demands of consumers and our customers on a timely basis. The

emergence of such potential competition and our inability to anticipate and effectively respond to changes on a

timely basis could have a material adverse effect on our business.

### The health care industry is experiencing changes due to political, economic and regulatory influences that could

### materially adversely affect our business.

The health care industry is highly regulated and subject to changing political, economic, and regulatory influences.

In recent years, the health care industry has undergone, and is in the process of undergoing, significant changes

driven by various efforts to reduce costs, including, among other factors: trends toward managed care; collective

purchasing arrangements and consolidation among office-based health care practitioners; and changes in

reimbursements to customers, including increased attention to value-based payment arrangements, as well as

growing enforcement activities (and related monetary recoveries) by governmental officials. Both our profitability

and the profitability of our customers may be materially adversely affected by laws and regulations reducing

reimbursement rates for pharmaceuticals, medical supplies and devices, and/or medical treatments or services, or

changes to the methodology by which reimbursement levels are determined. If we are unable to react effectively to

these and other changes in the health care industry, our business could be materially adversely affected. The ACA

greatly expanded health insurance coverage in the United States and has been the target of litigation and

Congressional reform efforts since its adoption. Any outcome of future court cases that change the ACA, in

addition to future legislation, regulation, guidance and/or Executive Orders that do the same, could have a

significant impact on the U.S. healthcare industry and the ability or willingness of individuals to engage with it.

### Expansion of GPOs, DSOs or provider networks and the multi-tiered costing structure may place us at a

### competitive disadvantage.

The health care products industry is subject to a multi-tiered costing structure, which can vary by manufacturer

and/or product. Under this structure, certain institutions can obtain more favorable prices for health care products

than we are able to obtain. The multi-tiered costing structure continues to expand as many large integrated health

care providers and others with significant purchasing power, such as GPOs and DSOs, demand more favorable

pricing terms. Additionally, the formation of provider networks, GPOs and DSOs may shift purchasing decisions

to entities or persons with whom we do not have a historical relationship and may threaten our ability to compete

effectively, which could in turn negatively impact our financial results. In addition, such organizations may

establish direct relationships with manufacturers, thereby either eliminating or reducing the services historically

provided by distributors. Although we are seeking to obtain similar terms from manufacturers to access lower

prices demanded by GPO and DSO contracts or other contracts, and to develop relationships with existing and

emerging provider networks, GPOs and DSOs, we cannot guarantee that such terms will be obtained or contracts

executed.

***Increases in shipping costs or service issues with our third-party shippers could harm our business.***

Our ability to meet our customers’ expedited delivery expectations is an integral component of our business

strategy for which our customers rely. Shipping is a significant expense in the operation of our business. We ship

almost all of our orders through third-party delivery services, and typically bear the cost of shipment. Accordingly,

any significant increase in shipping rates could have a material adverse effect on our business, financial condition

or operating results. While we have recently experienced increases in the cost of shipping, we do not expect these

additional expenses to be material to our results. However, it is possible that such costs could be material in the

future. Similarly, strikes or other service interruptions by those shippers, including at transportation centers or

shipping ports, could cause our operating expenses to rise and materially adversely affect our ability to deliver

products on a timely basis.

### MACRO-ECONOMIC AND POLITICAL RISKS

### Uncertain global and domestic macro-economic and political conditions could materially adversely affect our

### results of operations and financial condition.

Uncertain global and domestic macro-economic and political conditions that affect the economy and the economic

outlook of the United States, Europe, Asia, and other parts of the world could materially adversely affect our results

of operations and financial condition. These uncertainties, include, among other things:

election results;

changes to laws and policies governing foreign trade, tariffs and sanctions, or greater restrictions on

imports and exports;

supply chain disruptions;

changes in laws and policies governing health care or data privacy;

changes to the relationship between the United States and China;

sovereign debt levels;

the inability of political institutions to effectively resolve actual or perceived economic, currency or

budgetary crises or issues;

consumer confidence;

unemployment levels (and a corresponding increase in the uninsured and underinsured population);

changes in regulatory and tax regulations;

interest rate fluctuations, and strengthening of the dollar, which have and will continue to impact our

results of operations;

availability of capital;

increases in fuel and energy costs;

the effect of inflation on our ability to procure products and our ability to increase prices over time and

pass through to our customers price increases we may receive;

changes in tax rates and the availability of certain tax deductions;

increases in labor costs or health care costs;

the threat or outbreak of war, terrorism or public unrest (including, without limitation, the war in

Ukraine, the Israel-Gaza war and other unrest and threats in the Middle East, and the possibility of a

wider European or global conflict); and

changes in laws and policies governing manufacturing, development, and investment in territories and

countries where we do business.

Additionally, changes in government, government debt and/or budget crises may lead to reductions in government

spending in certain countries, which could reduce overall health care spending, and/or higher income or corporate

taxes, which could depress spending overall. Recessionary or inflationary conditions and depressed levels of

consumer and commercial spending may also cause customers to reduce, modify, delay, or cancel plans to purchase

our products and may cause suppliers to reduce their output or change their terms of sale. We have experienced

inflationary pressures, including higher freight costs and interest expense. Although inflation impacts both our

revenues and costs, the depth and breadth of our product portfolio often allows us to offer lower-cost national brand

solutions or corporate brand alternatives to our more price-sensitive customers who are unable to absorb price

increases, thus positioning us to protect our gross profit. The strengthening of the dollar, likewise, has impacted

our revenues and costs, but neither inflation nor exchange rates have materially impacted our results of operations

in fiscal year 2023. We generally sell products to customers with payment terms. If customers’ cash flow or

operating and financial performance deteriorate, or if they are unable to make scheduled payments or obtain credit,

they may not be able to, or may delay, payment to us. Likewise, for similar reasons suppliers may restrict credit or

impose different payment terms.

### REGULATORY AND LITIGATION RISKS

### Failure to comply with existing and future regulatory requirements could materially adversely affect our

### business.

We strive to be compliant with the applicable laws, regulations and guidance described below in all material

respects, and believe we have effective compliance programs and other controls in place to ensure substantial

compliance. However, compliance is not guaranteed either now or in the future as certain laws, regulations and

guidance may be subject to varying and evolving interpretations that could affect our ability to comply, as well as,

future changes, additions and enforcement approaches, including in light of political changes. When we discover

situations of non-compliance we seek to remedy them and bring the affected area back into compliance. Changes

with respect to the applicable laws, regulations and guidance described below may require us to update or revise

our operations, services, marketing practices, and compliance programs and controls, and may impose additional

and unforeseen costs on us, pose new or previously immaterial risks to us, or may otherwise have a material

adverse effect on our business. There can be no assurance that current and future government regulations will not

adversely affect our business, and we cannot predict new regulatory priorities, the form, content or timing of

regulatory actions, and their impact on the health care industry and on our business and operations.

Global efforts toward healthcare cost containment continue to exert pressure on product pricing. In the United

States, in addition to other government efforts to control health care costs, there has been increased scrutiny on drug

pricing and concurrent efforts to control or reduce drug costs by Congress, the President, executive branch agencies

and various states. We and our subsidiaries may be required to report drug pricing data under federal laws and

regulations. At the state level, several states have adopted laws, that may apply to some of our operations, that

require drug manufacturers, including re-packagers or re-labelers, to provide advance notice of certain price

increases and to report information relating to those price increases, while others have taken legislative or

administrative action to establish prescription drug affordability boards or multi-payer purchasing pools to reduce

the cost of prescription drugs. At the federal level, several related bills have been introduced and regulations

proposed which, if enacted or finalized, respectively, would impact drug pricing and related costs.

Under the Sunshine Act, we are required to collect and report detailed information regarding certain financial

relationships we have with covered recipients, including physicians, dentists, teaching hospitals, and certain other

non-physician practitioners. We and our subsidiaries may be required to report information under certain state transparency laws that address circumstances not covered by the Sunshine Act, and some of these state laws, as well as the federal law, can be unclear. We are also subject to foreign regulations requiring transparency of certain interactions between suppliers and their customers. While we believe we have substantially compliant programs and controls in place satisfying the above laws and requirements, such compliance imposes additional costs on us and the requirements are sometimes unclear. In the United States, government actions to seek to increase health- related price transparency may also affect our business.

Our business is subject to additional requirements under various local, state, federal and international laws and

regulations applicable to the sale and distribution of, and third-party payment for, pharmaceuticals and medical

devices and HCT/P products. Among the federal laws with which we must comply are the Controlled Substances

Act, the FDC Act, the Federal Drug Quality and Security Act, including DSCSA, Section 361 of the Public Health

Services Act and Section 401 of the Consolidated Appropriations Act of the Social Security Act. Among other

things, such laws, and the regulations promulgated thereunder:

regulate the introduction, manufacture, advertising, marketing and promotion, sampling, pricing and

reimbursement, labeling, packaging, storage, handling, returning or recalling, reporting, and

distribution of, and record keeping for drugs, HCT/P products and medical devices, including

requirements with respect to unique medical device identifiers;

subject us to inspection by the FDA and DEA and similar state authorities;

regulate the storage, transportation and disposal of certain of our products that are considered

hazardous materials;

require us to advertise and promote our drugs and devices in accordance with applicable FDA

requirements;

require us to report average sales price (ASP) for drugs or biologicals payable under Medicare Part B to

CMS with or without a Medicaid drug rebate agreement;

require registration with the FDA and the DEA and various state agencies;

require record keeping and documentation of transactions involving drug products;

require us to design and operate a system to identify and report suspicious orders of controlled

substances to the DEA and certain states;

require us to manage returns of products that have been recalled and subject us to inspection of our

recall procedures and activities;

impose on us reporting requirements if a pharmaceutical, HCT/P product or medical device causes

serious illness, injury or death;

require manufacturers, wholesalers, re-packagers and dispensers of prescription drugs to identify and

trace certain prescription drugs as they are distributed;

require the licensing of prescription drug wholesalers and third-party logistics providers; and

mandate compliance with standards for the recordkeeping, storage and handling of prescription drugs,

and associated reporting requirements.

The FDA has become increasingly active in addressing the regulation of computer software and digital health

products intended for use in health care settings. The Cures Act, signed into law on December 13, 2016, among

other things, amended the medical device definition to exclude certain software from FDA regulation, including

certain clinical decision support software. On September 27, 2019, the FDA issued a suite of guidance documents

on digital health products, which incorporated applicable Cures Act standards, and on September 28, 2022, the

FDA subsequently finalized certain of these guidance documents, including regarding the types of clinical decision

support tools and other software that are exempt from regulation by the FDA as medical devices, and the FDA

continues to issue new guidance in this area. Certain of our businesses involve the development and sale of

software and related products to support physician and dental practice management, and it is possible that the FDA

or foreign government authorities could determine that one or more of our products is subject to regulation as a

medical device, which could subject us or one or more of our businesses to substantial additional requirements,

costs and potential enforcement actions or liabilities for noncompliance with respect to these products. Some of our

imaging software is regulated as a medical device which subjects our businesses to substantial additional

requirements, costs and potential enforcement actions or liabilities for noncompliance with respect to these

products.

Applicable federal, state, local, and foreign laws and regulations also may require us to meet various standards

relating to, among other things, licensure or registration, program eligibility, procurement, third-party

reimbursement, sales and marketing practices, product integrity, and supply tracking to product manufacturers,

product labeling, personnel, privacy and security of health or other personal information, installation, maintenance

and repair of equipment and the importation and exportation of products. The FDA and DEA, as well as CMS

(including with respect to complex Medicare reimbursement requirements applicable to our specialty home medical

supplies business) and state Medicaid agencies, have recently increased their regulatory and enforcement activities

and, in particular, the DEA has heightened enforcement activities due to the opioid crisis in the United States. Our

business is also subject to requirements of similar and other foreign governmental laws and regulations affecting

our operations abroad.

The failure to comply with any of these laws or regulations, or new interpretations of existing laws and regulations,

or the imposition of any additional laws and regulations, could materially adversely affect our business. The costs

to us associated with complying with the various applicable statutes and regulations, as they now exist and as they

may be modified, could be material. Allegations by a governmental body that we have not complied with these

laws could have a material adverse effect on our businesses. While we believe that we are substantially compliant

with applicable laws and regulations, and believe we have adequate compliance programs and controls in place to

ensure substantial compliance, if it is determined that we have not complied with these laws, we are potentially

subject to warning letters, substantial civil and criminal penalties, mandatory recall of product, seizure of product

and injunction, consent decrees and suspension or limitation of payments to us, product sale and distribution. If we

enter into settlement agreements to resolve allegations of non-compliance, we could be required to make settlement

payments or be subject to civil and criminal penalties, including fines and the loss of licenses. Non-compliance

with government requirements could also adversely affect our ability to participate in important federal and state

government health care programs, such as Medicare and Medicaid, and damage our reputation.

### The EU Medical Device Regulation (“MDR”) may adversely affect our business.

The EU MDR, applicable since May 26, 2021, significantly modifies and intensifies the regulatory compliance

requirements for the medical device industry as a whole. Among other things, the EU MDR:

strengthens the rules on placing devices on the market and reinforces surveillance once they are

available;

establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the quality,

performance and safety of devices placed on the market;

improves the traceability of medical devices throughout the supply chain to the end-user or patient

through a unique identification number;

sets up a central database to provide patients, healthcare professionals and the public with

comprehensive information on products available in the EU;

strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to

undergo an additional check by experts before they are placed on the market; and

identifies importers and distributors and medical device products through registration in a database

(EUDAMED not due, for the time being, until the end of 2027 at the earliest, as mentioned above).

In particular, the EU MDR imposes strict requirements for the confirmation that a product meets the regulatory

requirements, including regarding a product’s clinical evaluation and a company’s quality systems, and for the

distribution, marketing and sale of medical devices, including post-market surveillance. As mentioned above,

pursuant to Regulation 2023/607 and subject to certain conditions, medical devices that (i) obtained a certificate

under the EU Medical Device Directive from May 25, 2017, (ii) which was still valid on May 26, 2021, and (iii)

has not been subsequently withdrawn may, for the moment, continue to be placed on the market or put into service

until December 31, 2027 for higher risk devices or December 31, 2028 for medium and lower risk devices.

Nevertheless, EU MDR requirements regarding the distribution, marketing and sale including quality systems and

post-market surveillance have to be observed by manufacturers, importers and distributors as of the application date

(i.e., May 26, 2021). The modifications created by the EU MDR may have an impact on the way we design and

manufacture products and the way we conduct our business in the EEA.

### If we fail to comply with laws and regulations relating to health care fraud or other laws and regulations, we

### could suffer penalties or be required to make significant changes to our operations, which could materially

### adversely affect our business.

Certain of our businesses are subject to federal and state (and similar foreign) health care fraud and abuse, referral

and reimbursement laws and regulations with respect to their operations. Some of these laws, referred to as “false

claims laws,” prohibit the submission or causing the submission of false or fraudulent claims for reimbursement to

federal, state, and other health care payers and programs. Other laws, referred to as “anti-kickback laws,” prohibit

soliciting, offering, receiving or paying remuneration in order to induce or reward the referral of a patient or

ordering, purchasing, leasing or arranging for, or recommending ordering, purchasing or leasing of, items or

services that are paid for by federal, state and other health care payers and programs. Certain additional state and

federal laws, such as the federal Physician Self-Referral Law, commonly known as the “Stark Law,” prohibit

physicians and other health care professionals from referring a patient to an entity with which the physician (or

family member) has a financial relationship, for the furnishing of certain designated health services (for example,

durable medical equipment and medical supplies), unless an exception applies. Violations of Anti-Kickback

statutes or the Stark Law may be enforced as violations of the federal False Claims Act.

The fraud and abuse laws and regulations have been subject to heightened enforcement activity over the past few

years, and significant enforcement activity has been the result of “relators” who serve as whistleblowers by filing

complaints in the name of the United States (and if applicable, particular states) under applicable false claims laws,

and who may receive up to 30% of total government recoveries. Penalties under fraud and abuse laws may be

severe, including treble damages and substantial civil penalties under the federal False Claims Act, as well as

potential loss of licenses and the ability to participate in federal and state health care programs, criminal penalties,

or imposition of a corporate compliance monitor, which could have a material adverse effect on our business. Also,

these measures may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that

could require us to make changes in our operations or incur substantial defense and settlement expenses. Even

unsuccessful challenges by regulatory authorities or private relators could result in reputational harm and the

incurring of substantial costs. Most states have adopted similar state false claims laws, and these state laws have

their own penalties which may be in addition to federal False Claims Act penalties, as well as other fraud and abuse

laws.

With respect to measures of this type, the United States government (among others) has expressed concerns about

financial relationships between suppliers on the one hand and physicians, dentists, and other health care providers,

on the other. As a result, we regularly review and revise our marketing practices as necessary to facilitate

compliance.

Our aspirations, goals and disclosures related to environmental, social and governance matters and the focus on

regulators and private litigants among other things on related claims made by companies and funds expose us to

numerous risks, including reputational, financial, legal and other risks, that could have an adverse impact on us,

including on our stock price. California has adopted stringent new climate disclosure requirements, as has the EU,

and the SEC appears about to adopt expansive new disclosure requirements on climate change.

In the EU, the Directive No. 2019/1937 of October 23, 2019,

#### on the protection of persons who report breaches of

#### Union law,

organizes the legal protection of whistleblowers. This Directive covers whistleblowers reporting

breaches of certain EU laws, in particular as regards public health, the above-mentioned Directive No. 2001/83,

Regulation No. 726/2004 or, as regards data protection, the GDPR. The Directive protects a wide range of people

and includes former employees. All private companies with 50 or more employees are required to create effective

internal reporting channels. All EU Member States other than Poland and Estonia have now implemented the

Directive.

We also are subject to the requirements of the new Directive No. 2022/2464 on corporate sustainability reporting

(“CSR Directive”) adopted on December 14, 2022 and which has to be implemented by EU members states by July

6, 2024, at the latest. By amending Directives No. 2004/109, No. 2006/43, No. 2013/34 and Regulation No.

537/2014, the CSR Directive strengthens the existing rules on non-financial reporting by setting new requirements

for large companies to publish sustainability-related information and, in particular, disclose details about their risks

and impacts on environmental matters.

We

also are subject to certain United States and foreign laws and regulations concerning the conduct of our foreign

operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, German anti-corruption laws

and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records, which have been

the focus of increasing enforcement activity globally in recent years. Our businesses are generally subject to

numerous other laws and regulations that could impact our financial results, including, without limitation,

securities, antitrust, consumer protection, and marketing laws and regulations.

In the EU, both active and passive bribery are criminalized. The EU Council Framework Decision 2003/568/JHA

of 22 July 2003

#### on combating corruption in the private sector

establishes more detailed rules on the liability of

legal persons and deterrent sanctions. However, the liability of legal persons is regulated at a national level.

Failure to comply with fraud and abuse laws and regulations, and other laws and regulations, could result in

significant civil and criminal penalties and costs, including the loss of licenses and the ability to participate in

federal and state health care programs, and could have a material adverse effect on our business. We may

determine to enter into settlements, make payments, agree to consent decrees or enter into other arrangements to

resolve such matters. Intentional or unintentional failure to comply with settlement agreements or consent decrees

could materially adversely affect our business.

While we believe that we are substantially compliant with applicable fraud and abuse and other laws and

regulations, and believe we have adequate compliance programs and controls in place to ensure substantial

compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or changes in our

services or marketing practices in response to changes in applicable law or interpretation of laws, could have a

material adverse effect on our business.

### If we fail to comply with laws and regulations relating to the collection, storage and processing of sensitive

### personal information or standards in electronic health records or transmissions, we could be required to make

***significant changes to our products, or incur substantial fines, penalties, or other liabilities.***

Our businesses that involve physician and dental practice management products, and our specialty home medical

supply businesses, include electronic information technology systems that store and process personal health,

clinical, financial, and other sensitive information of individuals. These information technology systems may be

vulnerable to breakdown, wrongful intrusions, data breaches and malicious attack, which could require us to

expend significant resources to eliminate these problems and address related security concerns, and could involve

claims against us by private parties and/or governmental agencies.

We are directly or indirectly subject to numerous and evolving federal, state, local and foreign laws and regulations

that protect the privacy and security of personal information, such as HIPAA, CAN-SPAM, TCPA, Section 5 of the

FTC Act, the CCPA, and the CPRA that became effective on January 1, 2023. Laws and regulations relating to

privacy and data protection are continually evolving and subject to potentially differing interpretations. These

requirements may not be harmonized, may be interpreted and applied in a manner that is inconsistent from one

jurisdiction to another or may conflict with other rules or our practices. Our businesses’ failure to comply with

these laws and regulations could expose us to breach of contract claims, substantial fines, penalties and other

liabilities and expenses, costs for remediation and harm to our reputation. Also, evolving laws and regulations in

this area could restrict the ability of our customers to obtain, use or disseminate patient information, or could

require us to incur significant additional costs to re-design our products to reflect these legal requirements, which

could have a material adverse effect on our operations.

In addition, the European Parliament and the Council of the EU adopted the GDPR effective from May 25, 2018,

which increased privacy rights for Data Subjects, including individuals who are our customers, suppliers and

employees. The GDPR extended the scope of responsibilities for data controllers and data processors, and

generally imposes increased requirements and potential penalties on companies, such as us, that are either

established in the EU and process personal data of Data Subjects (regardless the Data Subject location), or that are

not established in the EU but that offer goods or services to Data Subjects in the EU or monitor their behavior in the

EU. Noncompliance can result in penalties of up to the greater of EUR 20 million, or 4% of global company

revenues (sanction that may be public), and Data Subjects may seek damages. Member states may individually

impose additional requirements and penalties regarding certain limited matters (for which the GDPR left some room of flexibility), such as employee personal data. With respect to the personal data it protects, the GDPR requires, among other things, controller accountability, consents from Data Subjects or another acceptable legal basis to process the personal data, notification within 72 hours of a personal data breach where required, data integrity and security, and fairness and transparency regarding the storage, use or other processing of the personal data. The GDPR also provides rights to Data Subjects relating notably to information, access, rectification, erasure of the personal data and the right to object to the processing.

On August 20, 2021, China promulgated the PIPL, which took effect on November 1, 2021. The PIPL imposes

specific rules for processing personal information and it also specifies that the law shall also apply to personal

information activities carried out outside China but for the purpose of providing products or services to PRC

citizens. Any non-compliance with these laws and regulations may subject us to fines, orders to rectify or terminate

any actions that are deemed illegal by regulatory authorities, other penalties, as well as reputational damage or legal

proceedings against us, which may affect our business, financial condition or results of operations. The PIPL

carries maximum penalties of CNY50 million or 5% of the annual revenue of entities that process personal data.

In the United States, the CCPA, which increases the privacy protections afforded California residents, became

effective January 1, 2020. The CCPA generally requires companies, such as us, to institute additional protections

regarding the collection, use and disclosure of certain personal information of California residents. Compliance

with the obligations imposed by the CCPA depends in part on how particular regulators interpret and apply them.

Regulations were released in August of 2020, but there remains some uncertainty about how the CCPA will be

interpreted by the courts and enforced by the regulators. If we fail to comply with the CCPA or if regulators assert

that we have failed to comply with the CCPA, we may be subject to certain fines or other penalties and litigation,

any of which may negatively impact our reputation, require us to expend significant resources, and harm our

business. Furthermore, California voters approved the CPRA on November 3, 2020, which will amend and expand

the CCPA, including by providing consumers with additional rights with respect to their personal information, and

creating a new state agency to enforce CCPA and CPRA. The CPRA came into effect on January 1, 2023, applying

to information collected by businesses on or after January 1, 2022.

Other states, as well as the federal government, have increasingly considered the adoption of similarly expansive

personal privacy laws, backed by significant civil penalties for non-compliance. While we believe we have

substantially compliant programs and controls in place to comply with the GDPR, CCPA, PIPL and CPRA

requirements, our compliance with data privacy and cybersecurity laws is likely to impose additional costs on us,

and we cannot predict whether the interpretations of the requirements, or changes in our practices in response to

new requirements or interpretations of the requirements, could have a material adverse effect on our business.

We also sell products and services that health care providers, such as physicians and dentists, use to store and

manage patient medical or dental records. These customers and we are subject to laws, regulations and industry

standards, such as HIPAA and the Payment Card Industry Data Security Standards, which require the protection of

the privacy and security of those records. Our products or services may be used as part of these customers’

comprehensive data security programs, including in connection with their efforts to comply with applicable data

privacy and security laws and contractual requirements. Perceived or actual security vulnerabilities in our products

or services, or the perceived or actual failure by us or our customers who use our products or services to comply

with applicable legal or contractual data privacy and security requirements, may not only cause us significant

reputational harm, but may also lead to claims against us by our customers and/or governmental agencies and

involve substantial fines, penalties and other liabilities and expenses and costs for remediation. Additionally, under

the GDPR, health data belong to the category of “sensitive data” and benefit from specific protection. Processing

of such data is generally prohibited, except for specific exceptions.

Certain of our businesses involve the manufacture and sale of electronic health record (EHR) systems and other

products linked to government supported incentive programs, where the EHR systems must be certified as having

certain capabilities designated in evolving standards, such as those adopted by CMS and ONC. In order to maintain

certification of our EHR products, we must satisfy the changing governmental standards. If any other EHR systems

do not meet these standards, yet have been relied upon by health care providers to receive federal incentive

payments, we may be exposed to risk, such as under federal health care fraud and abuse laws, including the False

Claims Act. Additionally, effective September 1, 2023, the OIG for HHS issued a final rule implementing civil

money penalties for information blocking as established by the Cures Act. OIG incorporated regulations published by ONC as the basis for enforcing information blocking penalties. Each information blocking violation carries a $1 million penalty. While we believe we are substantially in compliance with such certifications and with applicable fraud and abuse laws and regulations and that we have adequate compliance programs and controls in place to ensure substantial compliance, we cannot predict whether changes in applicable law, or interpretation of laws, or resulting changes in our compliance programs and controls, could have a material adverse effect on our business.

Moreover, in order to satisfy our customers and comply with evolving legal requirements, our products may need to

incorporate increasingly complex functionality, such as with respect to reporting and information blocking.

Although we believe we are positioned to accomplish this, the effort may involve increased costs, and our failure to

implement product modifications, or otherwise satisfy applicable standards, could have a material adverse effect on

our business.

Additionally, as electronic medical devices are increasingly connected to each other and to other technology, the

ability of these connected systems to safely and effectively exchange and use exchanged information becomes

increasingly important. As a medical device manufacturer, we must manage risks including those associated with

an electronic interface that is incorporated into a medical device.

***Tax legislation could materially adversely affect our financial results and tax liabilities.***

We are subject to the tax laws and regulations of the United States federal, state, and local governments, as well as

foreign jurisdictions. From time to time, various legislative initiatives may be proposed that could materially

adversely affect our tax positions. There can be no assurance that our effective tax rate will not be materially

adversely affected by legislation resulting from these initiatives. In addition, tax laws and regulations are extremely

complex and subject to varying interpretations. Although we believe that our historical tax positions are sound and

consistent with applicable laws, regulations and existing precedent, there can be no assurance that our tax positions

will not be challenged by relevant tax authorities or that we would be successful in any such challenge.

### We face inherent risk of exposure to product liability, intellectual property infringement and other claims in the

### event that the use of the products we sell results in injury.

Our business involves a risk of product liability, intellectual property infringement and other claims in the ordinary

course of business, and from time to time we are named as a defendant in cases as a result of our distribution of

products. Additionally, we own interests in companies that manufacture certain dental and medical products. As a

result, we could be subject to the potential risk of product liability, intellectual property infringement or other

claims relating to the manufacture and distribution of products by those entities. In addition, as our corporate brand

business continues to grow, purchasers of such products may increasingly seek recourse directly from us, rather

than the ultimate product manufacturer, for product-related claims. Another potential risk we face in the

distribution of our products is liability resulting from counterfeit or tainted products infiltrating the supply chain. In

addition, some of the products that we transport and sell are considered hazardous materials. The improper

handling of such materials or accidents involving the transportation of such materials could subject us to liability or

at least legal action that could harm our reputation.

### Customs policies or legislative import restrictions could hinder the Company’s ability to import goods necessary

***to our operations on a timely basis and result in government enforcement actions and/or sanctions.***

Government-imposed import policies and legislation regulating the import of goods and prohibiting the use of

forced labor or human trafficking could result in delays or the inability to import goods in a timely manner that are

necessary to our operations, and such policies or legislation could also result in financial penalties, other sanctions,

government enforcement actions and reputational harm. While the Company has policies against and seeks to

avoid the import of goods that are manufactured in whole or in part by forced labor or through human trafficking,

as a result of legislative and governmental policy initiatives, we may be subject to increasing potential delays,

added costs, supply chain disruption and other restrictions.

### GENERAL RISKS

### Our business operations, results of operations, cash flows, financial condition and liquidity may be negatively

### impacted by the effects of disease outbreaks, epidemics, pandemics, or similar wide-spread public health

### concerns and other natural or man-made disasters, such as terrorism, civil unrest, fire, and extreme weather

Our business operations, results of operations, cash flows, financial condition and liquidity may be negatively

impacted by the effects of disease outbreaks, epidemics, pandemics, similar wide-spread public health concerns and

other natural or man-made disasters, such as terrorism, civil unrest, fire, and extreme weather (“disasters”). For

example, as a global healthcare solutions company, the COVID-19 pandemic and the governmental responses to it

had, and may again have, a material adverse effect on our business, results of operations and cash flows and may

result in a material adverse effect on our financial condition and liquidity. The impacts and potential impacts from

the COVID-19 pandemic included, and could include as a result of other disasters, the following, among other

impacts:

significant volatility in supply, demand and selling prices for personal protective equipment (PPE), test

kits and related products;

reduction in peoples’ ability and willingness to be in public;

reduction in peoples’ ability and willingness to seek elective care;

interrupted operations of industries that use or manufacture the products we distribute;

impact of adapted business practices;

significant changes in political conditions;

volatility in the financial market; and

unavailability or impairment of our manufacturing, distribution, or other facilities, or firmwide systems

such as our information systems.

The impact from disasters may also exacerbate other risks discussed herein, any of which could have a material

adverse effect on us.

***Our global operations are subject to inherent risks that could materially adversely affect our business.***

Our global operations are subject to risks that could materially adversely affect our business. The risks that our

global operations are subject to include, among other things:

difficulties and costs relating to staffing and managing foreign operations;

difficulties and delays inherent in sourcing products, establishing channels of distribution and contract

manufacturing in foreign markets;

fluctuations in the value of foreign currencies;

uncertainties relating to trade agreements and international trade relationships;

longer payment cycles of foreign customers and difficulty of collecting receivables in foreign

jurisdictions;

repatriation of cash from our foreign operations to the United States;

regulatory requirements, including, without limitation, anti-bribery, anti-corruption and laws pertaining

to the accuracy of our internal books and records;

litigation risks, new or unanticipated litigation developments and the status of litigation matters;

unexpected difficulties in importing or exporting our products and import/export tariffs, quotas,

sanctions or penalties;

limitations on our ability under local laws to protect our intellectual property;

unexpected regulatory, legal, economic and political changes in foreign markets;

changes in tax regulations that influence purchases of capital equipment;

civil disturbances, geopolitical turmoil, including terrorism, war or political or military coups; and

risks associated with climate change, including physical risks such as impacts from extreme weather

events and other potential physical consequences, regulatory and technological requirements, market

developments, stakeholder expectations and reputational risk.

### Our future success is substantially dependent upon our senior management, and our revenues and profitability

### depend on our relationships with capable sales representatives, service technicians, and other personnel who

### interact directly with our customers, as well as customers, suppliers and manufacturers of the products that we

### distribute.

Our future success is substantially dependent upon the efforts and abilities of members of our existing senior

management, particularly Stanley M. Bergman, Chairman and Chief Executive Officer. In November 2022, Mr.

Bergman’s employment agreement was extended through December 31, 2025. Although the Company has an

internal succession plan for its senior leadership team, including Mr. Bergman, the loss of the services of Mr.

Bergman could have a material adverse effect on our business. We do not currently have “key man” life insurance

policies on any of our employees. Competition for senior management is intense, burnout and turn-over rates are

increasing workplace concerns, and we may not be successful in attracting and retaining key personnel.

Additionally, our future revenues and profitability depend on our ability to maintain satisfactory relationships with

qualified sales representatives, service technicians, and other personnel who interact directly with our customers, as

well as customers, suppliers, and manufacturers. If we fail to maintain our existing relationships with such persons

or fail to acquire relationships with such key persons in the future, our business may be materially adversely

affected.

***Disruptions in the financial markets may materially adversely affect the availability and cost of credit to us.***

Our ability to make scheduled payments or refinance our obligations with respect to indebtedness will depend on

our operating and financial performance, which in turn is subject to prevailing economic conditions and financial,

business and other factors beyond our control. Disruptions in the financial markets may materially adversely affect

the availability and cost of credit to us.

## Cybersecurity

As filed, 3,012 characters.

We rely on information systems in our business to obtain, rapidly process, analyze, manage and store customer,

product, supplier and employee data to, among other things: maintain and manage multiple information systems

worldwide to facilitate the purchase and distribution of thousands of inventory items from numerous distribution

centers; receive, process and ship orders on a timely basis; manage the accurate billing and collections for

thousands of customers; process payments to suppliers and vendors; provide products and services that maintain

certain of our customers’ electronic medical or dental records (including protected health information of their

patients) and maintain and manage global human resources, compensation and payroll systems. For these purposes,

we define “information systems” in a manner consistent with the definition contained in the new rules recently

adopted by the SEC to mean “electronic information resources, owned or used by the registrant, including physical

or virtual infrastructure controlled by such information resources, or components thereof, organized for the

collection, processing, maintenance, use, sharing, dissemination, or disposition of the registrant's information to

maintain or support the registrant's operations.”

Cybersecurity Risk Management and Strategy

We have developed and implemented a cybersecurity risk mitigation strategy intended to protect our information

systems. Our cybersecurity risk mitigation strategy is designed so that the Company’s cybersecurity program is

aligned with generally accepted cybersecurity standards and frameworks, in particular the NIST Cybersecurity

Framework, or “NIST CSF,” and our Company is externally audited, or certified, with ISO27001 partial scope.

We maintain an Office of Cybersecurity (“OCS”), led by our Chief Information Security Officer (“CISO”), which

oversees the operations of our cyber risk mitigation strategy. The OCS is a cross-functional, enterprise-wide

management team, which continuously evaluates our global cybersecurity program’s effectiveness and is focused

on maintaining and protecting our information systems. In overseeing the operations of our cyber risk mitigation strategy, the OCS partners with our Global Technology Solutions team, which is led by our Chief Technology

Officer (“CTO”) and is comprised of over one hundred professionals that support our information systems and

operations. Our cyber risk mitigation strategy includes monitoring for and addressing risks that materialize within

the Company’s information systems, as well as at our third-party vendors, suppliers and other third-party business

partners.

Our CISO reports to our CTO. Our CTO, who also serves as Senior Vice President, has more than 30 years of

experience leading large-scale global IT organizations and received a Bachelor of Business Administration in

Business Computer Information Systems and a Master of Business Administration from Hofstra University. See

also

## Properties

As filed, 901 characters.

Within our health care distribution segment (for properties with more than 100,000 square feet) we lease and/or

own approximately 5.7 million square feet of properties, consisting of distribution, office, showroom,

manufacturing and sales space, in locations including the United States, Australia, Austria, Belgium, Brazil,

Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan,

Liechtenstein, Luxembourg, Malaysia, Mexico, Morocco, the Netherlands, New Zealand, Poland, Portugal,

Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom.

Lease expirations range from 2024 to 2041.

We believe that our properties are in good condition, are well maintained and are suitable and adequate to carry on

our business. We have additional operating capacity at certain distribution center facilities.

## Legal proceedings

As filed, 165 characters.

For a discussion of Legal Proceedings, see

#### Note 16 – Commitments and Contingencies

of the Notes to the

Consolidated Financial Statements included under Item 8.

## Management's discussion and analysis

As filed, 20,168 characters.

### Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we

provide the following cautionary remarks regarding important factors that, among others, could cause future results

to differ materially from the forward-looking statements, expectations and assumptions expressed or implied

herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of

future performance. These forward-looking statements involve known and unknown risks, uncertainties and other

factors that may cause our actual results, performance and achievements or industry results to be materially

different from any future results, performance or achievements expressed or implied by such forward-looking

statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,”

“intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable

terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in

this Annual Report on Form 10-K, and in particular the risks discussed under the caption “Risk Factors” in Item 1A

of this report and those that may be discussed in other documents we file with the Securities and Exchange

Commission (“SEC”).

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results

include, but are not limited to: our dependence on third parties for the manufacture and supply of our products; our

ability to develop or acquire and maintain and protect new products (particularly technology products) and

technologies that achieve market acceptance with acceptable margins; transitional challenges associated with

acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well

as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human

resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our

governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or

other purchasing incentives; risks related to the sale of corporate brand products; security risks associated with our

information systems and technology products and services, such as cyberattacks or other privacy or data security

breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation,

competition from third-party online commerce sites) and consolidating market; changes in the health care industry;

risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs

for our products or other service issues with our third-party shippers; general global and domestic macro-economic

and political conditions, including inflation, deflation, recession, ongoing wars, fluctuations in energy pricing and

the value of the U.S. dollar as compared to foreign currencies, and changes to other economic indicators,

international trade agreements, potential trade barriers and terrorism; geopolitical wars; failure to comply with

existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to

comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with

laws and regulations relating to the collection, storage and processing of sensitive personal information or standards

in electronic health records or transmissions; changes in tax legislation; risks related to product liability, intellectual

property and other claims; risks associated with customs policies or legislative import restrictions; risks associated

with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public

health concerns and other natural or man-made disasters; risks associated with our global operations; litigation

risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our

senior management, employee hiring and retention, and our relationships with customers, suppliers and

manufacturers; and disruptions in financial markets. The order in which these factors appear should not be

construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control

or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction

of actual results. We undertake no duty and have no obligation to update forward-looking statements except as

required by law.

### Where You Can Find Important Information

We may disclose important information through one or more of the following channels: SEC filings, public

conference calls and webcasts, press releases, the investor relations page of our website (www.henryschein.com)

and the social media channels identified on the Newsroom page of our website.

### Recent Developments

During the years ended December 30, 2023 and December 31, 2022 we continued to experience a decrease in the

sales of PPE and COVID-19 test kits as compared to the comparable prior-year periods, primarily due to lower

market pricing of PPE and lower market demand for COVID-19 test kits.

While the U.S. economy has recently experienced inflationary pressures and strengthening of the U.S. dollar, their

impacts have not been material to our results of operations. Though inflation impacts both our revenues and costs,

the depth and breadth of our product portfolio often allows us to offer lower-cost national brand solutions or

corporate brand alternatives to our more price-sensitive customers who are unwilling to absorb price increases, thus

positioning us to protect our gross profit.

Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things,

our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment

valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax

contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of

compensation cost for certain share-based performance awards and cash bonus plans; and pension plan

assumptions.

#### Cybersecurity Incident

In addition to immaterial and unrelated prior incidents at certain of our subsidiaries, in October 2023 Henry Schein

experienced a cybersecurity incident that primarily affected the operations of our North American and European

dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle

management and patient relationship management solutions business, was not affected, and our manufacturing

businesses were mostly unaffected. Once we became aware of the issue, we took steps to assess, contain and

remediate this incident. We restored affected systems and applications, our distribution operations resumed and we

reactivated our ecommerce platform. We also notified law enforcement and our employees, customers, suppliers

and investors, informing them of both the incident and management’s efforts to mitigate its impact on our daily

operations and data maintained on the Company’s systems. Subsequently, on or about November 8, 2023, we

determined that the threat actor obtained personal and sensitive information maintained on our systems belonging to

certain third parties and since that date we have notified affected and potentially affected parties as appropriate.

The scope of personal and sensitive data impacted is still under investigation. On November 22, 2023, we

experienced a related disruption to our ecommerce platform and related applications, which has since been

remediated. As described in “Management’s Discussion & Analysis – 2023 Compared to 2022, the incident

adversely impacted our financial results for the fourth quarter and full year 2023. We also expect some short-term

residual impact on our financial results in 2024.

We maintain cybersecurity insurance, subject to certain retentions and policy limitations. With respect to the

October 2023 cybersecurity incident, we have a $60 million insurance policy, following a $5 million retention.

### Executive-Level Overview

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and

technology.

We

believe we are the world’s largest provider of health care products and services primarily to office-

based dental and medical practitioners, as well as alternate sites of care.

We

serve more than one million customers

worldwide including dental practitioners, laboratories, physician practices, and ambulatory surgery centers, as well

as government, institutional health care clinics and other alternate care clinics.

We

believe that we have a strong

brand identity due to our more than 91 years of experience distributing health care products.

We are headquartered in Melville, New York, employ approximately 25,000 people (of which approximately

11,500 are based outside of the United States) and have operations or affiliates in 33 countries and territories. Our

broad global footprint has evolved over time through our organic success as well as through contribution from

strategic acquisitions.

We

have established strategically located distribution centers around the world to enable us to better serve our

customers and increase our operating efficiency. This infrastructure, together with broad product and service

offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of

supply for our customers’ needs.

While our primary go-to-market strategy is in our capacity as a distributor, we also market and sell our own

corporate brand portfolio of cost-effective, high-quality consumable merchandise products, including in vitro

diagnostic devices, manufacture certain dental specialty products in the areas of implants, orthodontics and

endodontics, manufacture drug products, and repackage/relabel prescription drugs and/or devices.

We

have

achieved scale in these global businesses primarily through acquisitions, as manufacturers of these products

typically do not utilize a distribution channel to serve customers.

We

conduct our business through two reportable segments: (i) health care distribution and (ii) technology and

value-added services. These segments offer different products and services to the same customer base. Our global

dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other

institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency

medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as

group practices and integrated delivery networks, among other providers across a wide range of specialties.

The health care distribution reportable segment, combining our global dental and medical operating segments,

distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services,

branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant,

orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins.

Our global technology and value-added services business provides software, technology and other value-added

services to health care practitioners. Our technology business offerings include practice management software

systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy,

education, revenue cycle management and financial services on a non-recourse basis, e-services, practice

technology, network and hardware services, as well as consulting, and continuing education services for

practitioners.

A key element to grow closer to our customers is our One Schein initiative, which is a unified go-to-market

approach that enables practitioners to work synergistically with our supply chain, equipment sales and service and

other value-added services, allowing our customers to leverage the combined value that we offer through a single

program. Specifically, One Schein provides customers with streamlined access to our comprehensive offering of

national brand products, our corporate brand products and proprietary specialty products and solutions (including

implant, orthodontic and endodontic products). In addition, customers have access to a wide range of services,

including software and other value-added services.

#### Industry Overview

In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited

distributors capable of providing a broad array of products and services at low prices. It also has accelerated the

growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to

their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing

specialized management information support.

We

believe that the trend towards cost containment has the potential

to favorably affect demand for technology solutions, including software, which can enhance the efficiency and

facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies and transactions that we

undertook to expand our business, domestically and internationally, in part to address significant changes in the

health care industry, including consolidation of health care distribution companies, health care reform, trends

toward managed care, cuts in Medicare and collective purchasing arrangements.

#### Industry Consolidation

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented

and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices

or service organizations ranging in size from a few practitioners to a large number of practitioners who have

combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies

in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners

has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete

order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the

practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than

one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to

partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician

hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or

professional staff level; however, orders are delivered to the practitioners’ offices.

We

believe that consolidation within the industry will continue to result in a number of distributors, particularly

those with limited financial, operating and marketing resources, seeking to combine with larger companies that can

provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire

companies that can enhance their current product and service offerings or provide opportunities to serve a broader

customer base.

Our approach to acquisitions and joint ventures has been to expand our role as a provider of products and services

to the health care industry. This trend has resulted in our expansion into service areas that complement our existing

operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.

As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we

have the ability to support increased sales through our existing infrastructure, although there can be no assurances

that we will be able to successfully accomplish this.

We

also have invested in expanding our sales/marketing

infrastructure to include a focus on building relationships with decision makers who do not reside in the office-

based practitioner setting.

As the health care industry continues to change, we continually evaluate possible candidates for joint venture or

acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to

the health care industry. There can be no assurance that we will be able to successfully pursue any such

opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or

consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the

integration efforts associated with any such transaction would be successful.

#### Aging Population and Other Market Influences

The health care products distribution industry continues to experience growth due to the aging population,

increased health care awareness, the proliferation of medical technology and testing, new pharmacological

treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment on

insurance coverage. In addition, the physician market continues to benefit from the shift of procedures and

diagnostic testing from acute care settings to alternate-care sites, particularly physicians’ offices.

According to the U.S. Census Bureau’s International Database, between 2023 and 2033, the 45 and older

population is expected to grow by approximately 11%. Between 2023 and 2043, this age group is expected to grow

by approximately 21%. This compares with expected total U.S. population growth rates of approximately 6%

between 2023 and 2033 and approximately 11% between 2023 and 2043.

According to the U.S. Census Bureau’s International Database, in 2023 there are approximately seven million

Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care

services. By the year 2050, that number is projected to nearly triple to approximately 19 million. The population

aged 65 to 84 years is projected to increase by approximately 23% during the same period.

As a result of these market dynamics, annual expenditures for health care services continue to increase in the

United States. We believe that demand for our products and services will grow while continuing to be impacted by

current and future operating, economic, and industry conditions. The Centers for Medicare and Medicaid Services,

or CMS, published “National Health Expenditure Data” indicating that total national health care spending reached

approximately $4.5 trillion in 2022, or 17.3% of the nation’s gross domestic product, the benchmark measure for

annual production of goods and services in the United States. Health care spending is projected to reach

approximately $7.2 trillion by 2031, or 19.6% of the nation’s projected gross domestic product.

#### Government

Our businesses are generally subject to numerous laws and regulations that could impact our financial performance,

and failure to comply with such laws or regulations could have a material adverse effect on our business.

See “

## Market risk

As filed, 6,522 characters.

We are exposed to market risks, interest rate risks as well as changes in foreign currency exchange rates as

measured against the U.S. dollar and each other, and changes to the credit markets. We attempt to minimize these

risks primarily by using foreign currency forward contracts and by maintaining counter-party credit limits. These

hedging activities provide only limited protection against currency exchange and credit risks. Factors that could

influence the effectiveness of our hedging programs include currency markets and availability of hedging

instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are

components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated

currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by

diversifying our investments, maintaining a strong balance sheet and having multiple sources of capital.

#### Foreign Currency

The value of certain foreign currencies compared to the U.S. dollar may affect our financial results. Fluctuations in

exchange rates may positively or negatively affect our revenues, gross margins, operating expenses and retained

earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs

using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate

fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward

contracts to protect against currency exchange risks associated with intercompany loans due from our international

subsidiaries and the payment of merchandise purchases to foreign suppliers. We do not hedge the translation of

foreign currency profits into U.S. dollars, as we consider foreign currency translation to be an accounting exposure,

not an economic exposure. A hypothetical 5% change in the average value of the U.S. dollar in 2023 compared to

foreign currencies would have changed our 2023 reported Net income attributable to Henry Schein, Inc. by

approximately $5 million.

As of December 30, 2023, our forward foreign currency exchange agreements, which expire through November 3,

2028, had a fair value of $(8) million as determined by quoted market prices. Included in the forward foreign

currency exchange agreements, Henry Schein, Inc. had net investment designated EUR/USD forward contracts

with notional values of approximately €300 million and reported fair values of $(7) million. A 5% increase in the

value of the Euro to the USD from December 30, 2023 would decrease the fair value of these forward contracts by

$18 million.

#### Total Return Swaps

On March 20, 2020, we entered into a total return swap for the purpose of economically hedging our unfunded non-

qualified supplemental retirement plan and our deferred compensation plan obligation.

At inception, the notional value of the investments in these plans was $43 million. At December 30, 2023, the

notional value of the investments in these plans was $96 million. At December 30, 2023, the financing blended rate

for this swap was based on the Secured Overnight Financing Rate (“SOFR”) of 5.33% plus 0.52%, for a combined

rate of 5.85%. For the years ended December 30, 2023, December 31, 2022, and December 25, 2021 we have

recorded a gain/(loss), within selling, general and administrative expense, of approximately $10 million, $(17)

million and $12 million, respectively, net of transaction costs, related to this undesignated swap. This swap is

expected to be renewed on an annual basis and is expected to result in a neutral impact to our results of operations.

#### Credit Risk Monitoring

We limit our credit risk with respect to our cash equivalents, short-term investments and derivative instruments, by

monitoring the credit worthiness of the financial institutions who are the counterparties to such financial

instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing

numerous investment grade counterparties.

#### Interest Rate Risk

As of December 30, 2023, we had variable interest rate exposure for certain of our revolving credit facilities and

our U.S. trade accounts receivable securitization.

Our revolving credit facility which we entered into on July 11, 2023 and expires on July 11, 2028, has a variable

interest rate that is based on the SOFR plus a spread based on our leverage ratio at the end of each financial

reporting quarter. As of December 30, 2023, there was $200 million outstanding under this revolving credit

facility. During the year ended December 30, 2023, the average outstanding balance was approximately $61

million. Based upon our average outstanding balances, for each hypothetical increase of 25 basis points, our

interest expense thereunder would have increased by $0.2 million.

Our U.S. trade accounts receivable securitization, which we entered into on April 17, 2013 and expires on

December 15, 2025, has a variable interest rate that is based upon the asset-backed commercial paper rate. As of

December 30, 2023, the commercial paper rate was 5.67% plus 0.75%, for a combined rate of 6.42%, and the

outstanding balance under this securitization facility was $210 million. During the year ended December 30, 2023,

the average outstanding balance was approximately $238 million. Based upon our average outstanding balances,

for each hypothetical increase of 25 basis points, our interest expense thereunder would have increased by $1

million.

On July 11, 2023, we entered into interest rate swap agreements to hedge the cash flow of our variable rate $750

million floating debt term loan facility, with three years maturity, effectively changing the floating rate portion of

our obligation to a fixed rate. Under the terms of the interest rate swap agreements, we receive variable interest

payments based on the one-month Term SOFR rate and pay interest at a fixed rate. As of December 30, 2023, the

notional value of the interest rate swap agreements was $741 million. This term loan matures on July 11, 2026.

At December 30, 2023, the interest on this Term Credit Agreement was 5.36% plus 1.35% for a combined rate of

6.71%. However, we have a hedge in place (see

#### Note 12 – Derivatives and Hedging Activities

for additional

information) that ultimately creates an effective fixed rate of 5.79%.

## Controls and procedures

As filed, 14,341 characters.

#### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of management, including our principal executive officer and

principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and

procedures as of the end of the period covered by this annual report as such term is defined in Rules 13a-15(e) and

15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on

this evaluation, our management, including our principal executive officer and principal financial officer,

concluded that our disclosure controls and procedures were effective as of December 30, 2023, to ensure that all

material information required to be disclosed by us in reports that we file or submit under the Exchange Act is

accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and

that all such information is recorded, processed, summarized and reported within the time periods specified in the

SEC’s rules and forms, and the rules of the Nasdaq stock exchange.

#### Changes in Internal Control over Financial Reporting

During the quarter ended December 30, 2023, we acquired a 90% voting equity interest in Shield, a supplier of

homecare medical products headquartered in California. The full integration of this acquisition, as well as our

previously reported acquisitions of S.I.N and Biotech Dental, extended beyond year-end and, therefore, we

excluded Shield, Biotech Dental, and S.I.N., which together represent less than 1.5% of our total net sales, from our

annual assessment of internal control over financial reporting as of December 30, 2023, as permitted by SEC staff

interpretive guidance for newly acquired businesses.

Post-acquisition integration related activities for other dental and medical businesses acquired during 2023 across

the U.S., Europe, Brazil, Australia, and China were included in our annual assessment of internal control over

financial reporting as of December 30, 2023. These acquisitions, the majority of which utilize separate information

and financial accounting systems, have been included in our consolidated financial statements since their respective

dates of acquisition.

Finally, we continued systems implementation activities in the U.S. for two of our dental businesses.

The combination of acquisitions (including Shield, S.I.N., and Biotech Dental), continued acquisition integrations

and systems implementation activities undertaken during the quarter and carried over from prior quarters when

considered in the aggregate, represents a material change in our internal control over financial reporting.

During the quarter, all acquisitions, continued acquisition integrations and systems implementation activities

involve necessary and appropriate change-management controls that are considered in our quarterly assessment of

changes in our internal control over financial reporting.

In October 2023, we experienced a cybersecurity incident that primarily affected the operations of our North

American and European dental and medical distribution businesses. Once we became aware of the issue, as part of

the Company’s incident response plan, we took precautionary actions to contain the incident including shutting

down connectivity to networks and key business, operating and financial accounting systems globally. In addition

to notifying affected and potentially affected third parties and all relevant law enforcement authorities, we engaged

external cyber-security experts to support our assessment of the cyber-incident’s impact as well as sanitize, rebuild

and restore our affected systems and applications. We also notified law enforcement and our employees,

customers, suppliers and investors, informing them of both the incident and management’s efforts to mitigate its

impact on our daily operations and data maintained on the Company’s systems.

Subsequently, on or about November 8, 2023, we determined that the threat actor obtained personal and sensitive

information maintained on our systems belonging to certain third parties and since that date we have notified

affected parties and potentially affected parties as appropriate. The scope of personal and sensitive data impacted is

still under investigation.

On November 22, 2023, we experienced a related disruption to our ecommerce platform and related applications,

which has since been remediated.

In order to mitigate the impact of this disruption on our systems and on our ability to service customers, alternative

procedures and controls were temporarily implemented.

#### Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting,

as such term is defined in Exchange Act Rule 13a-15(f). Our internal control system is designed to provide

reasonable assurance to our management and Board regarding the preparation and fair presentation of published

financial statements. Under the supervision and with the participation of our management, including our principal

executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal

control over financial reporting based on the framework in Internal Control-Integrated Framework (2013), updated

and reissued by the Committee of Sponsoring Organizations, or the COSO Framework. Based on our evaluation

under the COSO Framework, our management concluded that our internal control over financial reporting was

effective at a reasonable assurance level as of December 30, 2023.

The effectiveness of our internal control over financial reporting as of December 30, 2023, has been independently

audited by BDO USA, P.C., an independent registered public accounting firm, and their attestation is included

herein. The evaluation of internal controls involves judgment. Our external auditor has concluded that the

Company has a material weakness resulting from the aggregation of certain control deficiencies at the application

control level related to logical and user access management and segregation of duties. The Company agrees that

there are control deficiencies that our external auditor has identified, all of which either have been addressed or are

being addressed. The Company’s management has considered the control deficiencies identified by our external

auditor, and believes that, individually and in aggregate, they do not result in a material weakness. A material

weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that

there is a reasonable possibility that a material misstatement of the company’s financial statements will not be

prevented or detected on a timely basis.

#### Limitations of the Effectiveness of Internal Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance

that the objectives of the internal control system are met. Because of the inherent limitations of any internal control

system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company

have been detected.

### Report of Independent Registered Public Accounting Firm

Shareholders and Board of Directors

Henry Schein, Inc.

Melville, NY

### Opinion on Internal Control over Financial Reporting

We have audited Henry Schein, Inc.’s (the “Company’s”) internal control over financial reporting as of December

30, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee

of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company did

not maintain, in all material respects, effective internal control over financial reporting as of December 30, 2023,

based on the COSO criteria.

We do not express an opinion or any other form of assurance on management’s statements referring to any

corrective actions taken by the Company after the date of management’s assessment.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board

(United States) (“PCAOB”), the consolidated balance sheets of the Company as of December 30, 2023 and

December 31, 2022, the related consolidated statements of income, comprehensive income, changes in

stockholders’ equity, and cash flows for each of the three years in the period ended December 30, 2023, and the

related notes (collectively referred to as “the financial statements”) and our report dated February 28, 2024

expressed an unqualified opinion thereon.

### Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and

for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying,

“Item 9A, Management’s Report on Internal Control over Financial Reporting”. Our responsibility is to express an

opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting

firm registered with the PCAOB and are required to be independent with respect to the Company in accordance

with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange

Commission and the PCAOB.

We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB.

Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective

internal control over financial reporting was maintained in all material respects. Our audit included obtaining an

understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and

testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our

audit also included performing such other procedures as we considered necessary in the circumstances. We believe

that our audit provides a reasonable basis for our opinion.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting,

such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim

consolidated financial statements will not be prevented or detected on a timely basis. We have identified the

following material weakness that has not been identified as a material weakness in management’s assessment. The

material weakness in internal control over financial reporting is related to logical and user access management and

segregation of duties, at the application control level, in certain information technology environments at certain

components. There is a reasonable possibility that a material misstatement of the Company’s annual or interim

consolidated financial statements with respect to these matters would not have been prevented or detected on a

timely basis. This material weakness was considered in determining the nature, timing, and extent of audit tests

applied in our audit of the 2023 consolidated financial statements, and this report does not affect our report dated

February 28, 2024, on those consolidated financial statements.

As indicated in the accompanying “Item 9A, Management’s Report on Internal Control over Financial Reporting”,

management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not

include the internal controls of Shield Healthcare, Inc., S.I.N. Implant System, and Biotech Dental, which were acquired during the year ended December 30, 2023, and are included in the consolidated balance sheet of the

Company as of December 30, 2023, and the related consolidated statements of income, comprehensive income,

changes in stockholders’ equity, and cash flows for the year then ended. Shield Healthcare, Inc., S.I.N. Implant

System, and Biotech Dental, together represent less than 1.5% of total net sales for the year ended December 30,

2023\. Management did not assess the effectiveness of internal control over financial reporting of Shield Healthcare,

Inc., S.I.N. Implant System, or Biotech Dental because of the timing of the acquisitions which were completed

during the year ended December 30, 2023. Our audit of internal control over financial reporting of the Company

also did not include an evaluation of the internal control over financial reporting of Shield Healthcare, Inc., S.I.N.

Implant System, or Biotech Dental.

### Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance

regarding the reliability of financial reporting and the preparation of financial statements for external purposes in

accordance with generally accepted accounting principles. A company’s internal control over financial reporting

includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,

accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable

assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance

with generally accepted accounting principles, and that receipts and expenditures of the company are being made

only in accordance with authorizations of management and directors of the company; and (3) provide reasonable

assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the

company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect

misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that

controls may become inadequate because of changes in conditions, or that the degree of compliance with the

policies or procedures may deteriorate.

/s/ BDO USA, P.C.

New York , NY

February 28, 2024

Filed Feb 28, 2024.
Source: SEC EDGAR, the filing index for accession 0001000228-24-000011. Last ingested by Listed: Nov 12, 2026, 17:42 ET. No prices; not investment advice.
